Quarterlytics / Industrials / Xebec Adsorption Inc.

Xebec Adsorption Inc.

xbc · TSX-V Industrials
Claim this profile
Ticker xbc
Exchange TSX-V
Sector Industrials
Industry
Employees 201-500
← All annual reports
FY2021 Annual Report · Xebec Adsorption Inc.
Sign in to download
Loading PDF…
Xebec Adsorption Inc. 
Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(Expressed in thousands of Canadian dollars) 

 
Raymond Chabot 
Grant Thornton LLP 
Suite 2000 
National Bank Tower 
600 De La Gauchetière Street West 
Montréal, Quebec 
H3B 4L8 
T  514-878-2691 
 
 
 
 
 
 
Member of Grant Thornton International Ltd 
rcgt.com
 
Independent Auditor's Report 
To the Shareholders of 
Xebec Adsorption Inc. 
Opinion 
We have audited the consolidated financial statements of Xebec Adsorption Inc. 
(hereafter "the Company"), which comprise the consolidated statements of financial 
position as at December 31, 2021 and 2020, and the consolidated statements of 
loss, the consolidated statements of comprehensive loss, the consolidated 
statements of changes in equity and the consolidated statements of cash flows for 
the years then ended, and notes to consolidated financial statements, including a 
summary of significant accounting policies. 
In our opinion, the accompanying consolidated financial statements present fairly, in 
all material respects, the financial position of the Company as at December 31, 2021 
and 2020, and its financial performance and its cash flows for the years then ended 
in accordance with International Financial Reporting Standards (IFRS). 
Basis for opinion 
We conducted our audit in accordance with Canadian generally accepted auditing 
standards. Our responsibilities under those standards are further described in the 
"Auditor’s responsibilities for the audit of the consolidated financial statements" 
section of our report. We are independent of the Company in accordance with the 
ethical requirements that are relevant to our audit of the consolidated financial 
statements in Canada, and we have fulfilled our other ethical responsibilities in 
accordance with these requirements. We believe that the audit evidence we have 
obtained is sufficient and appropriate to provide a basis for our opinion.
Key audit matters 
Key audit matters are those matters that, in our professional judgement, were of most 
significance in our audit of the consolidated financial statements of the current period. 

2
These matters were addressed in the context of our audit of the consolidated 
financial statements as a whole, and in forming our opinion thereon, and we do not 
provide a separate opinion on these matters. 
Percentage of completion of contracts in progress at year-end 
As described in note 1 to the consolidated financial statements, revenues from long-
term production-type contracts such as biogas purification equipment and 
engineering service contracts are determined under the percentage of completion 
method whereby revenues are recognized based on the costs incurred to date in 
relation to the total expected costs of a contract (costs being composed mainly of 
materials and labour). We identified the determination of the percentage of 
completion of contracts in progress at year-end as a key audit matter. 
Why the matter was determined to be key audit matter 
The determination of the percentage of completion was significant to our audit 
because management’s assessment of the percentage of completion requires 
significant judgements (see note 1), including milestones marked, actual work 
performed and estimated costs to complete. These significant judgements can have 
a material impact on the amounts of revenue and profit recognized. 
How the matter was addressed in the audit 
Our audit procedures related to management's estimate of percentage of completion 
of contracts at year-end included, among others: 
– 
We reviewed, on a sample basis, contractual arrangements, including pricing 
and billing terms, contract changes, and terms and conditions; 
– 
We confirmed, on a sample basis, contracts terms directly with customers; 
– 
We tested, on a sample basis, costs incurred to date; 
– 
We compared, on a sample basis, the estimates of costs to complete made in 
the prior period to actual contract costs incurred in the current period to assess 
management’s ability to estimate the costs to complete a contract; 
– 
We tested, on a sample basis, future costs to complete the contracts to purchase 
orders and quotes obtained by management; 
– 
We tested, on a sample basis, anticipated losses on contracts recorded in the 
current period; and 
– 
We conducted inquiries with management and project managers to gain an 
understanding of the status of contract activities. 
Valuation of assets acquired and liabilities assumed in business combinations 
As described in note 1 to the consolidated financial statements, the Company applies 
the acquisition method in accounting for business combinations. The Company 
completed the final purchase price allocation for the business combinations 

3
described in note 2 to the consolidated financial statements. Under the acquisition 
method of accounting, management determines the fair value of assets acquired and 
liabilities assumed (with certain exceptions). We identified the valuation of assets 
acquired and liabilities assumed in business combinations as a key audit matter. 
Why the matter was determined to be key audit matter 
The valuation of assets acquired and liabilities assumed in business combinations 
was significant to our audit because it involves significant judgement from 
management and a high degree of subjectivity and effort, including the need to 
involve fair value specialists. In particular, the fair value of the intangible assets and 
contingent consideration is dependent on the outcome of many variables, including 
the acquirees’ future cash flows and profitability. 
How the matter was addressed in the audit 
Our audit procedures related to the valuation of assets acquired and liabilities 
assumed included, among others: 
– 
We reviewed the share purchase agreements; 
– 
With the assistance of our valuation specialists, we evaluated the 
reasonableness of management’s projections of future cash flows by comparing 
the projections to historical results; 
– 
With the assistance of our valuation specialists, we evaluated the 
reasonableness of the valuation methodologies and discount rates by: 
o 
Testing information used to determine the discount rates; 
o 
Performing sensitivity analysis by developing a range of independent 
estimates for the discount rates and comparing those to the discount rates 
applied by management. 
– 
With the assistance of our valuation specialists, we evaluated the 
reasonableness of attrition rates of customer relationships; and 
– 
We tested the fair values of the other assets and liabilities included upon the 
acquisition which were not subject to cash flow projection valuation methods. 
Annual test for impairment 
As described in Note 1 to the consolidated financial statements, the Company is 
required to annually test for impairment cash-generating units (CGU) to which 
goodwill has been allocated. We identified the Company's annual test for impairment 
as a key audit matter. 
Why the matter was determined to be key audit matter 
This annual impairment test was significant to our audit because the amount of 
goodwill of $163,464,000 as at December 31, 2021 is material to the consolidated 
financial statements. In addition, management’s determination of recoverable 

4
amounts of CGUs involves significant judgement from management and a high 
degree of subjectivity and efforts, including the need to involve fair value specialists. 
How the matter was addressed in the audit 
Our audit procedures related to the Company’s evaluation of the recoverable amount 
included, among others: 
– 
With the assistance of our valuation specialists, we evaluated the 
reasonableness of the methodologies to calculate the recoverable amount. We 
also evaluated the reasonableness of the significant assumptions used by the 
Company, in particular those relating to growth rates, profit margins and discount 
rates, which are key to the outcome of the impairment test. We did this by 
developing independent discount rates and assumptions, and performing 
sensitivity analysis; 
– 
We assessed the adequacy of the Company’s disclosures about those 
assumptions to which the outcome of the impairment test is most sensitive, that 
is, those that have the most significant effect on the determination of the 
recoverable amount. 
Information other than the consolidated financial statements and the auditor’s 
report thereon 
Management is responsible for the other information. The other information 
comprises the information included in the Management's Discussion and Analysis. 
Our opinion on the consolidated financial statements does not cover the other 
information and we do not and will not express any form of assurance conclusion 
thereon. In connection with our audit of the consolidated financial statements, our 
responsibility is to read the other information identified above and, in doing so, 
consider whether the other information is materially inconsistent with the 
consolidated financial statements or our knowledge obtained in the audit, or 
otherwise appears to be materially misstated. 
We obtained the Management's Discussion and Analysis prior to the date of this 
auditor’s report. If, based on the work we have performed on this other information, 
we conclude that there is a material misstatement of this other information, we are 
required to report that fact in this auditor’s report. We have nothing to report in this 
regard. 
Responsibilities of management and those charged with governance for the 
consolidated financial statements 
Management is responsible for the preparation and fair presentation of the 
consolidated financial statements in accordance with International Financial 
Reporting Standards (IFRS), and for such internal control as management 
determines is necessary to enable the preparation of consolidated financial 
statements that are free from material misstatement, whether due to fraud or error. 

5
In preparing the consolidated financial statements, management is responsible for 
assessing the Company's ability to continue as a going concern, disclosing, as 
applicable, matters related to going concern and using the going concern basis of 
accounting unless management either intends to liquidate the Company or to cease 
operations, or has no realistic alternative but to do so. 
Those charged with governance are responsible for overseeing the Company’s 
financial reporting process. 
Auditor’s responsibilities for the audit of the consolidated financial statements 
Our objectives are to obtain reasonable assurance about whether the consolidated 
financial statements as a whole are free from material misstatement, whether due to 
fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable 
assurance is a high level of assurance, but is not a guarantee that an audit conducted 
in accordance with Canadian generally accepted auditing standards will always 
detect a material misstatement when it exists. Misstatements can arise from fraud or 
error and are considered material if, individually or in the aggregate, they could 
reasonably be expected to influence the economic decisions of users taken on the 
basis of these consolidated financial statements. 
As part of an audit in accordance with Canadian generally accepted auditing 
standards, we exercise professional judgement and maintain professional skepticism 
throughout the audit. We also: 
– 
Identify and assess the risks of material misstatement of the consolidated 
financial statements, whether due to fraud or error, design and perform audit 
procedures responsive to those risks, and obtain audit evidence that is sufficient 
and appropriate to provide a basis for our opinion. The risk of not detecting a 
material misstatement resulting from fraud is higher than for one resulting from 
error, as fraud may involve collusion, forgery, intentional omissions, 
misrepresentations, or the override of internal control; 
– 
Obtain an understanding of internal control relevant to the audit in order to 
design audit procedures that are appropriate in the circumstances, but not for 
the purpose of expressing an opinion on the effectiveness of the Company’s 
internal control; 
– 
Evaluate the appropriateness of accounting policies used and the 
reasonableness of accounting estimates and related disclosures made by 
management; 
– 
Conclude on the appropriateness of management’s use of the going concern 
basis of accounting and, based on the audit evidence obtained, whether a 
material uncertainty exists related to events or conditions that may cast 
significant doubt on the Company's ability to continue as a going concern. If we 
conclude that a material uncertainty exists, we are required to draw attention in 
our auditor’s report to the related disclosures in the consolidated financial 

6
statements or, if such disclosures are inadequate, to modify our opinion. Our 
conclusions are based on the audit evidence obtained up to the date of our 
auditor’s report. However, future events or conditions may cause the Company 
to cease to continue as a going concern; 
– 
Evaluate the overall presentation, structure and content of the consolidated 
financial statements, including the disclosures, and whether the consolidated 
financial statements represent the underlying transactions and events in a 
manner that achieves fair presentation; 
– 
Obtain sufficient appropriate audit evidence regarding the financial information 
of the entities or business activities within the group to express an opinion on 
the consolidated financial statements. We are responsible for the direction, 
supervision and performance of the group audit. We remain solely responsible 
for our audit opinion. 
We communicate with those charged with governance regarding, among other 
matters, the planned scope and timing of the audit and significant audit findings, 
including any significant deficiencies in internal control that we identify during our 
audit. 
We also provide those charged with governance with a statement that we have 
complied with relevant ethical requirements regarding independence, and to 
communicate with them all relationships and other matters that may reasonably be 
thought to bear on our independence, and where applicable, related safeguards. 
From the matters communicated with those charged with governance, we determine 
those matters that were of most significance in the audit of the consolidated financial 
statements of the current period and are therefore the key audit matters. We describe 
these matters in our auditor's report unless law or regulation precludes public 
disclosure about the matter or when, in extremely rare circumstances, we determine 
that a matter should not be communicated in our report because the adverse 
consequences of doing so would reasonably be expected to outweigh the public 
interest benefits of such communication. 
The engagement partner on the audit resulting in this independent auditor’s report is 
Louis Roy. 
1
Montreal 
March 16, 2022 
1  CPA auditor, CA public accountancy permit no. A125741 

 
 
Xebec Adsorption Inc. 
Consolidated Statements 
 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
The accompanying notes are an integral part of these consolidated financial statements 
Consolidated Statements of Loss 
 
 
  
  
2021 
$  
2020 
$ 
 
  
  
  
 
Revenue from contracts 
 
 
122,914
56,520
Government grants 
 
 
2,987
-
Revenue (Note 3) 
 
 
125,901
56,520
 
 
Cost of goods sold 
 
 
96,397
56,254
 
 
Gross margin 
 
 
29,504
266
 
 
Research and development expenses 
 
 
1,584
1,223
Selling and administrative expenses  
 
 
51,813
21,568
Share of after-tax profit of equity accounted investees 
 
 
(703)
213
Other (gains) and losses (Note 4) 
 
 
(8,794) 
6,480
 
 
 
 
43,900
29,484
 
 
Operating loss 
 
 
(14,396)
(29,218)
 
 
Other charges (income) 
 
 
Net Finance expenses (Note 5) 
 
 
6,484
2,749
 
 
Loss before income taxes 
 
 
(20,880)
(31,967)
 
 
Income taxes (Note 6) 
 
 
2,570
(9)
 
 
Net loss for the year 
 
 
(23,450)
(31,958)
Net loss per share 
Basic and diluted (Note 7) 
 
 
(0.15)
(0.33)
 
 
 

 
Xebec Adsorption Inc. 
Consolidated Statements 
 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
 
 
 
 
 
 
Consolidated Statements of Comprehensive Loss 
 
  
2021 
$  
2020 
$ 
 
  
  
 
 
Net loss for the year 
 
 
(23,450)
(31,958)
 
 
Other comprehensive loss 
 
 
Items that will be reclassified subsequently to profit or loss 
Cumulative translation adjustment 
 
 
(14,921)
333
 
 
Comprehensive loss for the year 
 
 
(38,371)
(31,625)
 
 
 
 
 
The accompanying notes are an integral part of these consolidated financial statements 

 
Xebec Adsorption Inc. 
Consolidated Statements 
 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
 
 
 
 
 
 
Consolidated Statements of Financial Position 
 
 
 
 
 
December 31,
2021
$
 
December 31, 
2020 
 $ 
Assets 
 
 
(restated - note 2) 
Current assets 
 
 
 
Cash  
 
39,905
160,938 
Restricted cash (Note 2) 
 
11,214
7,642 
Trade and other receivables (Note 8) 
 
 
61,570
35,123 
Inventories (Note 9) 
 
 
52,693
20,865 
Investment tax credits receivable 
 
 
-
16 
Finance leases receivable (Note 10) 
 
 
410
129 
Prepaid expenses 
 
 
1,446
1,131 
Total current assets 
 
 
167,238
225,844 
Non-current assets 
 
 
 
Finance leases receivable (Note 10) 
 
 
9,053
3,016 
Investment in associates and joint ventures (Note 26) 
 
 
21,663
116 
Deferred financing costs 
 
 
3,616
985 
Property, plant and equipment (Note 11) 
 
 
42,687
36,973 
Intangible assets (Note 12) 
 
 
88,820
67,602 
Goodwill (Note 13) 
 
 
163,464
117,842 
Other non-current assets 
 
 
46
53 
Total non-current assets  
 
329,349
226,587 
Total assets 
 
 
496,587
452,431 
Liabilities 
 
 
 
Current liabilities  
 
 
 
Credit facility (Note 14) 
 
 
5,000
975 
Trade, other payables and accrued liabilities (Note 15) 
 
 
33,359
27,905 
Contract liabilities (Note 16) 
 
 
29,730
7,689 
Current portion of long-term debt (Note 17) 
 
 
13,735
14,052 
Current portion of government royalty program obligation (Note 17) 
 
 
207
185 
Current portion of provisions (Note 18) 
 
 
1,780
1,541 
Current portion of obligation arising from shares issued by a subsidiary 
 
 
-
2,972 
Income taxes payable  
 
 
1,325
109 
 
 
 
Total current liabilities 
 
 
85,136
55,428 
 
 
 
Non-current liabilities 
 
 
 
Long-term debt (Note 17) 
 
 
69,356
42,774 
Government royalty program obligation (Note 17) 
 
 
-
183 
Provisions (Note 18) 
 
 
3,049
348 
Deferred tax liabilities (Note 6) 
 
 
24,236
16,410 
 
 
 
Total non-current liabilities 
 
 
96,641
59,715 
 
 
 
Total liabilities 
 
 
181,777
115,143 
 
 
 
Equity 
 
 
 
Share capital (Note 7) 
 
 
398,566
389,864 
Contributed surplus 
 
 
15,337
8,145 
Accumulated other comprehensive loss 
 
 
(15,835)
(914) 
Deficit 
 
 
(83,258)
(59,807) 
Total equity 
 
 
314,810
337,288 
 
 
 
Total liabilities and equity 
 
 
496,587
452,431 
 
 
 
The accompanying notes are an integral part of these consolidated financial statements 
Approved by the Board of Directors  
__________________________________ Director 
___________________________________ Director
(signed) William Beckett 
(signed) Peter Bowie 

Xebec Adsorption Inc. 
Consolidated Statements of Changes in Equity 
(expressed in Canadian dollars) 
 
 
 
Number 
 
 
 
 
 
Amount 
 
Common 
shares 
 
Warrants and 
Compensation Shares 
Share capital 
– Common 
shares 
Contributed 
surplus 
Accumulated
other
comprehensive
income (loss)
Deficit 
Total 
 
 
$
$
$
$
$
Balance – December 31, 2019 
84,378,678
11,975,544
63,484
4,570
(1,247)
(27,849)
38,958
Net loss for the year 
-
-
-
-
-
(31,958)
(31,958)
Other comprehensive loss 
-
-
-
-
333
-
333
Comprehensive loss for the year 
-
-
-
-
333
(31,958)
(31,625)
Issuance of warrants from new financing (Note 7) 
-
3,000,000
-
2,953
-
-
2,953
Shares issued from the exercise of options (Note 7) 
1,903,333
-
682
(319)
-
-
363
Shares issued and to be issued from public offering (Note 7) 
43,676,724
-
221,245
-
-
-
221,245
Shares issued following business acquisition (Note 2) 
10,014,364
-
83,384
-
-
-
83,384
Warrants and compensation shares issued from public offering 
(Note 7) 
-
826,965
(631)
631
-
-
-
Warrants and compensation shares exercised from public 
offering (Note 7) 
12,369,887
(12,369,887)
21,700
(742)
-
-
20,958
Warrants from public offering – Cancelled  
-
(14,355)
-
-
-
-
-
Share-based compensation expense (Note 19)  
-
-
-
1,052
-
-
1,052
Balance – December 31, 2020 
152,342,986
3,418,267
389,864
8,145
(914)
(59,807)
337,288
Net loss for the year 
-
-
-
-
-
(23,450)
(23,450)
Other comprehensive loss 
-
-
-
-
(14,921)
-
(14,921)
Comprehensive loss for the year 
-
-
-
-
(14,921)
(23,450)
(38,371)
Issuance of warrants from financing (Note 7) 
-
4,500,000
-
6,986
-
-
6,986
Shares issued from the exercise of options (Note 7) 
102,831
-
244
(196)
-
-
48
Shares issued from arising from the prior departure of employees 
(note 4) 
735,294
-
2,000
-
-
-
2,000
Warrants and compensation shares exercised (Note 7) 
418,267
(418,267)
2,001
(586)
-
-
1,415
Shares issued following business acquisition (Note 2) 
1,118,556
-
4,457
-
-
-
4,457
Share-based compensation expense (Note 7) 
-
-
-
988
-
-
988
 
Balance – December 31, 2021 
154,717,934
7,500,000
398,566
15,337
(15,835)
(83,258)
314,810
Accumulated other comprehensive loss relates solely to cumulative translation adjustments
The accompanying notes are an integral part of these consolidated financial statements. 

Xebec Adsorption Inc. 
Consolidated Statements of Cash Flows 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
 
 
 
 
 
 
 
 
 
 
 
2021 
$ 
2020
$
Cash flows from    
 
Operating activities 
 
 
Net loss for the year 
(23,450) 
(31,958)
Items not affecting cash 
 
Depreciation and amortization (Note 11 and 12) 
12,166 
3,785
Inventory write-down 
(19) 
111
Accretion finance expenses and gain on revaluation of government royalty 
program obligation (Note 17) 
14 
20
Accretion of earn-out (Note 17) 
1,081 
38
Accretion of the obligation arising from shares issued by a subsidiary 
120
306
Exchange gain/loss on the obligation arising from shares issued by a subsidiary 
(45)
217
Share-based compensation expense (Note 19) 
988 
1,052
Share of after-tax profit of equity accounted investees 
(703) 
213
Gain on deconsolidation of a subsidiary 
(2,154) 
-
Remeasurement of investment 
(18,968) 
-
Future income taxes 
1,634 
(430)
Other operating activities 
103 
503
Change in non-cash working capital balances related to operations (Note 20) 
(27,468) 
(619)
(56,701) 
(26,762)
Investing activities 
 
Business acquisitions, net of cash acquired (Note 2) 
(71,483) 
(70,827)
Acquisition of property, plant and equipment 
(9,581) 
(492)
Acquisition of intangible assets 
(1,947) 
(775)
Transfer to restricted cash          
(3,804) 
(7,537)
Other investing activities 
(348) 
(116)
 
(87,163) 
(79,747)
Financing activities 
 
Increase of credit facility (Note 14) 
4,986 
974
Accretion of debt liabilities (Note 17) 
- 
308
Payment of debt liabilities (Note 17) 
(14,855) 
(997)
Proceeds from issuance of share capital (Notes 7) 
3,463 
242,566
EDC repayment (Note 17) 
- 
(6,340)
EDC loan Holding USA (Note 17) 
18,971 
4,604
FTQ Investment, net of financing costs (Note 17) 
9,862 
4,918
CEBA loan (Note 17) 
67 
-
Government assistance (Note 17) 
- 
519
Repayment of government royalty program obligation (Note 17) 
(175) 
(118)
Repayment of the obligation arising from shares issued by a subsidiary 
- 
(1,731)
22,319 
244,703
Net (decrease) increase in cash during the year 
(121,545) 
138,194
Cash – Beginning of the year 
160,938 
22,358
Effect of exchange rate changes on cash  
512 
386
Cash– End of the year 
39,905 
160,938
 
 
 
The accompanying notes are an integral part of these consolidated financial statements. 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(2) 
 
These consolidated financial statements have been prepared in accordance with International Financial Reporting 
Standards (“IFRS”) and were approved and authorized for issue by the Board of Directors of the Company on 
March 16, 2022. 
1 
Nature of business and summary of significant accounting policies 
Xebec Adsorption Inc. (“Xebec” or the “Company”) is a global provider of clean energy solutions and specialized 
in the design and manufacture of cost-effective and environmentally responsible purification, separation, 
dehydration and filtration equipment for gases and compressed air. Xebec’s main product lines are biogas 
upgrading systems for the purification of biogas from agricultural digesters, landfill sites and waste water 
treatment plants, natural gas dryers for natural gas refuelling stations, associated gas purification systems which 
enable diesel displacement on drilling sites, and hydrogen purification and generation systems for fuel cell and 
industrial applications, on-site oxygen and nitrogen generators for industrial, energy and healthcare applications 
and provide services for the compressed air and gas businesses. The Company is incorporated and domiciled in 
Canada and is listed on the TSX Exchange under the symbol XBC since January 7, 2021. It was previously listed 
on the TSX Venture (TSXV) Exchange under the symbol XBC-V. The address of its registered office is 730 
Industriel Boulevard, Blainville, Quebec, Canada. 
The continued spread of COVID-19 around the globe and the responses of governmental authorities and corporate 
entities, including through mandated or voluntary shutdowns, have and may continue to lead to a general slow-
down in the economy and to disruptions to our workforce and facilities, our customers, our sales and operations 
and our supply chain. 
The full extent and impact of the COVID-19 pandemic is unknown and at this stage the future is very difficult to 
project.  
The Company’s bad debt expense may increase, revenues and cash resources may be negatively affected, and the 
Company may need to assist potential customers with obtaining financing or government incentives to help them 
fund their purchases of our products. Any temporary suspension of production in Xebec facilities, or those of any 
of its suppliers, partners or customers, as a direct result of COVID-19 may have a material adverse effect on the 
Company. 
Basis of compliance and basis of preparation 
The consolidated financial statements have been prepared on the historical cost convention, except where IFRS 
requires recognition at fair value. 
These consolidated financial statements are based on the accounting policies as described below. 
These policies have been consistently applied to all periods, unless otherwise stated. 
Certain figures of the consolidated statements have been reclassified to comply with the basis of presentation 
adopted in the current year (Note 2). 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(3) 
 
Segment reporting 
The Company operates three business segments: 
• 
Systems (Cleantech) – Includes Renewable Natural Gas, Hydrogen and Renewable Hydrogen for a 
variety of applications, from fuel cells to fossil fuel replacement applications for low carbon 
transportation fuels and project development of renewable natural gas production facilities, in the build, 
own and operate (BOO) model that will generate low-carbon renewable transport fuels and carbon credits; 
• 
Support (Industrial Products and Services) – foundational recurring revenue model; and 
• 
Corporate and other – Includes corporate functions. 
 
Infrastructure is no longer reported due to its activities being rolled into a non-controlling joint venture. The 
reporting structure reflects the way the Company is managed and how it classifies its operations for planning and 
measuring performance. 
For management purposes, the Company uses the same measurement policies as those outlined in its financial 
statements. 
In addition, corporate assets are used by each segment and are therefore not attributable to any segment 
specifically. 
Basis of consolidation 
These consolidated financial statements include the accounts of the Company and its subsidiaries. Subsidiaries 
are entities controlled by the Company. Control is achieved when the Company: 
• 
Has power over the investee; 
• 
Is exposed, or has rights, to variable returns from its involvement with the investee; and  
• 
Has the ability to use its power to affect its returns.  
 
The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are 
changes to one or more of the three elements of control listed above.  
When the Company has less than a majority of the voting rights of an investee, it has power over the investee 
when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee 
unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the 
Company's voting rights in an investee are sufficient to give it power, including:  
• 
The size of the Company's holding of voting rights relative to the size and dispersion of holdings of the 
other vote holders;  
• 
Potential voting rights held by the Company, other vote holders or other parties;  
• 
Rights arising from other contractual arrangements; and  
• 
Any additional facts and circumstances that indicate that the Company has, or does not have, the current 
ability to direct the relevant activities at the time that decisions need to be made, including voting patterns 
at previous shareholders' meetings.  

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(4) 
 
Subsidiaries are fully consolidated from the date on which control is obtained by the Company and are 
deconsolidated from the date that control ceases. All intercompany accounts and transactions have been 
eliminated. 
Changes in the Company's ownership interests in subsidiaries that do not result in the Company losing control 
over the subsidiaries are accounted for as equity transactions or liability transactions depending on the conditions 
that these changes occurred. The carrying amounts of the Company's interests are adjusted to reflect the changes 
in their relative interests in the subsidiaries. 
Investments in associated and joint ventures  
Investments in associated and joint ventures are accounted for using the equity method (Note 26). 
Under the equity method of accounting, interests in joint ventures are initially recognized at cost and adjusted 
thereafter to recognize the Company’s share of the profits or losses and movements in other comprehensive 
income (OCI) of the investee. 
Business acquisitions 
The Company applies the acquisition method in accounting for business acquisitions. The consideration 
transferred by the Company to obtain control of a subsidiary is calculated as the sum of the acquisition-date fair 
value of assets transferred, liabilities incurred and the equity interest issued by the Company, which includes the 
fair value of any asset or liability arising from a contingent consideration arrangement. Acquisition costs are 
expensed as incurred. 
Inventories 
Inventories are stated at the lower of cost and net realizable value for raw materials, sub-assembly parts, work-
in-progress and finished goods. Costs of raw materials are determined on an average cost basis or by using the 
first-in first-out method. Work in progress, sub-assembly parts and finished goods include materials, direct labour 
and production overhead. Net realizable value is the estimated selling price for inventories less all estimated costs 
of completion and costs necessary to make the sale. Inventories are recorded net of any obsolescence provision. 
A new assessment is made in each subsequent year when inventories are adjusted to net realizable value. When 
the circumstances that previously caused inventories to be written down below cost no longer exist or when there 
is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount 
of the write-down is reversed and the reversal is limited to the amount of the original write-down, so that the new 
carrying amount is the lower of cost and the revised net realizable value. 
 
Property, plant and equipment 
Property, plant and equipment is stated at cost less accumulated depreciation and accumulated impairment losses. 
Cost includes expenditures that are directly attributable to the acquisition or the manufacturing of the asset 
including borrowing costs capitalized. Manufacturing price is comprised of the cost of raw materials and 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(5) 
 
consumables, plus expenditures directly attributable to an asset’s manufacturing and installation, including labour 
costs. Subsequent costs, such as replacement of parts or major inspections, are included in the asset’s carrying 
amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits 
associated with the item will flow to the Company and the cost can be measured reliably. The carrying amount of 
a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated 
statement of income (loss) during the year in which they are incurred. 
The major categories of property, plant and equipment are depreciated on a straight-line basis as follows: 
Right-of-use-assets 
Lease term 
Machinery and production equipment 
3 to 30 years 
Office furniture and equipment 
2 to 10 years 
Leased equipment 
15 years 
Leasehold improvement 
Lease term 
 
The Company allocates the amount initially recognized in respect of an item of property, plant and equipment to 
its significant components and depreciates each such component separately. Residual values, method of 
depreciation and useful lives of the assets are reviewed annually and adjusted if appropriate. 
Assets under construction are related to expenditures for production equipment and lease equipment in the course 
of construction.  Depending on the complexity of the asset, the time required to complete the construction ranges 
between 12 and 32 months. 
Gains and losses on disposals of property, plant and equipment are determined by comparing the proceeds with 
the carrying amount of the asset and are included as part of other gains and losses in the consolidated statement 
of income (loss). 
Identifiable intangible assets 
The Company’s intangible assets consist of software, capitalized development costs, engineering standardisation 
costs, customer relationships, trademarks and expenditures on design and production of new or substantially 
improved products and processes when the criteria mentioned in the research and development expenses 
accounting policy are met. From business acquisitions, intangible assets consist of trade names and customer 
relationships. These assets are capitalized and amortized on a straight-line basis in the consolidated statement of 
income (loss) over the period of their expected useful lives. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(6) 
 
The Company’s Research & Development concentrates on the development of gas generator to improve and 
develop designs and processes.  The time required for a developed process and/or design to be completed and 
available for its intended use ranges between 24 and 36 months. 
Development costs are amortized over a period of five years. Engineering standardisation costs and software are 
amortized over a period of three to five years. Customer relationships, technology and trade names are amortized 
over a period of eight to twenty years.  
Impairment of non-financial assets 
Cash-generating units (“CGUs”) to which goodwill has been allocated are tested for impairment at least annually. 
All other individual assets or cash-generating units are tested for impairment whenever events or changes in 
circumstances indicate that the carrying amount may not be recoverable. For the purpose of measuring recoverable 
amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). 
The recoverable amount is the higher of an asset’s fair value less costs to sell and its value in use (being the 
present value of the expected future cash flows of the relevant asset or CGU). An impairment loss is recognized 
for the amount by which the asset’s carrying amount exceeds its recoverable amount. 
Impairment losses for CGUs reduce the carrying amount of any goodwill allocated to that CGU. Any remaining 
impairment loss is charged pro rata to the other assets in the CGU. 
The Company evaluates impairment losses for potential reversals when events or circumstances warrant such 
consideration, with the exception of goodwill. 
Goodwill 
Goodwill represents the future economic benefits arising from business acquisitions that are not individually 
identified and separately recognised. Goodwill is carried at cost less accumulated impairment losses. 
Provisions 
Provisions for warranties and legal claims, where applicable, are recognized in accrued liabilities when the 
Company has a present legal or constructive obligation as a result of past events and it is more likely than not that 
an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. 
Provisions are measured at management’s best estimate of the expenditure required to settle the obligation at the 
end of the reporting year and are discounted to present value where the effect is material. The Company performs 
evaluations to identify onerous contracts and, where applicable, records provisions for such contracts. 
During the normal course of its operations, the Company assumes certain maintenance and repair costs under 
warranties offered on natural gas equipment, biogas, associated gas and hydrogen purification equipment. The 
warranties cover a period ranging from 12 to 18 months. A liability for the expected cost of the warranty-related 
claims is established when the product is delivered and completed. In estimating the warranty liability, historical 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(7) 
 
material replacement costs and the associated labour costs are considered. Revisions are made when actual 
experience differs materially from historical experience. 
Financial Instruments 
The Company’s financial assets and liabilities are accounted for at amortized cost. 
• 
Cash; 
• 
Restricted cash; 
• 
Trade and other receivables; 
• 
Finance leases receivables; 
• 
Credit facility; 
• 
Trade, other payables and accrued liabilities; 
• 
Long-term debt; and 
• 
Government royalty program obligation. 
Except for those trade receivables that do not contain a significant financing component and are measured at the 
transaction price in accordance with IFRS 15, all financial assets are initially measured at fair value adjusted for 
transaction costs where applicable. 
Financial assets, other than those designated and effective as hedging instruments, are classified into the following 
categories: 
• 
Amortized cost; 
• 
Fair value through profit or loss (FVTPL); and 
• 
Fair value through other comprehensive income (FVOCI). 
 
In the periods presented, the Company does not have any financial assets categorized as FVTPL or FVOCI. 
The classification is determined by both the Company’s business model for managing the financial assets and the 
contractual cash flow characteristics of the financial asset. 
All income and expenses relating to financial assets that are recognized in income or loss are presented within 
finance expenses or finance income, except for impairments of trade receivables which are presented within 
selling and administrative expenses. 
Financial assets are measured at amortized cost if the assets meet the following conditions and are not designated 
as FVTPL: 
• 
They are held within a business model whose objective is to hold the financial assets and collect its 
contractual cash flows; 
• 
The contractual terms of the financial assets give rise to cash flows that are solely payments of principal 
and interest on the principal amount outstanding. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(8) 
 
After initial recognition, they are measured at amortized cost using the effective interest method. Discounting is 
omitted where the effect of discounting is immaterial.  
The Company considers a broader range of information when assessing credit risk and measuring expected credit 
losses, including past events, current conditions, and reasonable and supportable forecasts that affect the expected 
collectability of the future cash flows on the instrument. If the financial instrument has not deteriorated 
significantly in credit quality since initial recognition or has low credit risk, the Company considers that there are 
no expected credit losses. 
In applying this forward-looking approach, a distinction is made between: 
• 
Financial instruments that have not deteriorated significantly in credit quality since initial recognition or 
that have low credit risk (“Stage 1”); and 
• 
Financial instruments that have deteriorated significantly in credit quality since initial recognition and 
whose credit risk in not low (“Stage 2”). 
 
“Stage 3” would cover financial assets that have objective evidence of impairment at the reporting date. 
“12-month expected credit losses” are recognized for the first category while “lifetime expected credit losses” are 
recognized for the second category. 
Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over 
the expected life of the financial instrument. 
Financial liabilities are initially measured at fair value and where applicable, adjusted for transaction costs unless 
the Company designated a financial liability at fair-value through profit or loss. 
Subsequently, financial liabilities are measured at amortized cost using the effective interest method. All interest-
related charges and, if applicable, changes in an instrument’s fair value that are reported in income or loss are 
included within finance expense or finance income. 
Government royalty program obligations 
The Company receives from time to time, from different government agencies, funding designed to promote 
economic growth, create jobs and support sustainable development. In some of these arrangements, the Company 
has a contractual obligation to repay the contributions to the government agency, with repayments determined as 
a percentage of specified revenues over a contractually defined royalty year. Such arrangements are recognized 
as government royalty program obligations at initial recognition when the contribution is received. These 
obligations are estimated based on future projections, discounted using a rate that reflects the liability-specific 
risks. Over time, interest expense is recognized as a result of accretion of the long-term obligations, while royalty 
payments are recorded against the obligations. Subsequently, the government royalty program obligations are re-
measured using the original discount rate when the future projections initially used to measure the obligations are 
revised. Resulting changes in the carrying amount of these obligations are recognized in the consolidated 
statement of income (loss) as finance income or finance expense. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(9) 
 
Share Capital 
Share capital represents the amount received from the issue of shares, less issuance costs, net of any underlying 
income tax benefit from these issuance costs. If shares are issued when options and warrants are exercised, the 
share capital account also comprises the compensation costs previously recorded as contributed surplus. If shares 
are issued within the conversion option on the exercise of convertible debentures, the share capital account also 
includes the equity component of such convertible debentures.  
 
Proceeds from unit placements are allocated between shares and warrants according to the residual value method, 
where the difference between the fair value and issue price of the shares when the warrants are issued is allocated 
to the warrants.  
 
Basic and Diluted Net Loss per Share 
Basic income (loss) per share is calculated by dividing net income (loss) for the year attributable to equity owners 
of the Company by the weighted average number of common shares outstanding during the year (Note 7). 
Diluted income (loss) per share is calculated by adjusting the weighted average number of common shares 
outstanding for dilutive instruments. The number of shares included for options and similar instruments is 
computed assuming that if all dilutive securities had been exercised at the later of the beginning of the year and 
the date of issuance, the proceeds would be used to purchase common shares at the average market value during 
the year. 
Revenues from Contracts with Customers 
The Company earns revenues mainly from the sale of natural gas dryers, air dryers and hydrogen purification 
solutions (commercial equipment). The Company recognizes revenue on commercial equipment sales when it is 
probable that the economic benefits will flow to the Company and delivery has occurred. These criteria are 
generally met at the time the product is shipped and delivered to the customer and, depending on the delivery 
conditions, title and risk have passed to the customer. Provisions are established for estimated product returns and 
warranty costs at the time revenue is recognized. Cash received in advance is recorded as contract liabilities.  
Revenues from long-term production-type contracts such as biogas purification equipment and engineering 
service contracts are determined under the percentage-of-completion method whereby revenues are recognized 
based on the costs incurred to date in relation to the total expected costs of a contract (costs being composed 
mainly of materials and labour). Costs and estimated profit on contracts in progress in excess of amounts billed 
are reflected as contract assets. Cash received in advance of revenues being recognized on contracts is recorded 
as contract liabilities.  
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(10) 
 
The Company monitors its contracts with customers on a regular basis to determine if a loss is likely to occur. If 
a loss is anticipated on a contract, the entire estimated loss is recorded as a cost of goods sold in the year in which 
the loss becomes evident and reasonably estimable.  
Revenues are measured based on the price specified in the sales contract, net of discounts and estimated returns 
at the time of sale. Historical experience is used to estimate and provide for discounts and returns. 
Revenues for contracts in China are recognized upon completion and the Company can determine that control has 
been transferred to the customer in accordance with the agreed-upon specifications in the contract. 
Revenues from services are recorded when services have been rendered. For contract services that last over a 
year, revenue is recognized over the duration of the contract.  
Gas generators and installation revenue comprises the sale of assets which are manufactured based on customer 
specific needs and requirements. The Company considers these contracts as one performance obligation. The 
Company manufactures an asset which would have no alternative use in its completed state and the Company is 
entitled to receive consideration during the manufacturing period. Consideration received is not refundable to 
customers to the extent that costs have been incurred during the manufacturing process. The Company recognises 
revenue over the time of the manufacturing process. Revenue is measured using the input method whereby 
revenue is recognised based on the pro rata cost incurred in relation to the total estimated cost to manufacture. 
The manufacturing process for an asset is estimated to be less than 12 months based on experience. The Company 
therefore applies the practical expedient in IFRS 15.63 whereby an entity does not adjust the consideration to be 
received for the effects of a significant financing component.  
Service and maintenance revenue comprises the after-sale maintenance; and servicing of the asset which was 
transferred to the customer on an annual subscription contract. The service and maintenance revenue is a distinct 
performance obligation to provide an undefined quantity of services over the duration of the contract period. A 
portion of the transaction price is therefore allocated to service and maintenance based on the stand-alone selling 
price of those services. Discounts are not considered as they are only given in rare circumstances and are never 
material. Revenue is recognised over the duration of the contract.  
Revenues from Gas-as-a-Service (GaaS) are addressed in lease section.  
Contract balances 
Contract assets are recognized when goods or services are transferred to customers before consideration is 
received or before the Company has an unconditional right to payment for performance completed to date. 
Contract assets are subsequently transferred to receivables when the right of payment becomes unconditional. 
Contract assets include costs incurred and recorded margins in excess of advances and progress billings on long-
term contracts. 
Contract liabilities are recognized when amounts are received from customers in advance of transfer of goods or 
services. Contract liabilities are subsequently recognized in revenue as or when the Company performs under 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(11) 
 
contracts. Contract liabilities include advances and progress billings in excess of long-term contract costs incurred 
and recorded margins. 
A net position of contract asset or contract liability is determined for each contract. The cash flows in respect of 
advances and progress billings are classified as cash flows from operating activities. 
Costs to obtain or fulfill a contract 
The Company recognizes as an asset the incremental costs of obtaining a contract with a customer when those 
costs are expected to be recovered.  
Costs that would have been incurred regardless of whether the contract was obtained are recognized as an expense 
when incurred unless those costs are explicitly chargeable to the customer regardless of whether the contract is 
obtained. 
The Company recognizes the incremental costs of obtaining contracts as an expense when incurred because those 
costs are not expected to be recovered and are not charged to the customer. 
 
Remaining performance obligations 
The Company’s contracts are for delivery of goods within the 12 months following a contract’s signature; 
therefore, the Company uses the practical expedient allowed in Paragraph 121(a) of IFRS 15. 
Following Paragraph 121(a), the Company does not disclose the aggregate amount of the transaction price 
allocated to the performance obligations that are unsatisfied as at the end of the reporting period.  
Government grants 
Non-refundable grants relating to property, plant and equipment are accounted for as deferred government grants 
and amortized on the same basis as the related assets. 
Research and experimental development tax credits are recognized using the cost reduction method when there 
is reasonable assurance of their recovery. Investment tax credits are subject to the customary approvals by the 
pertinent tax authorities. Adjustments, if required, are reflected in the year when such assessments are received. 
Government grants are recognised where there is reasonable assurance that the grants will be received and all 
attached conditions will be met. The Company’s grants are related to an expense item and recognised as income 
on a systematic basis over the period the related costs, for which it is intended to be compensated. Government 
grants are deducted from the respective expense lines unless they relate to R&D projects, in which case they are 
presented as governments grants under total income.  
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(12) 
 
Leases 
The Company as a lessee: 
The Company recognises a right-of-use asset and a lease liability with respect to a lease on the date the underlying 
asset is available for use by the Company (hereafter, the ‘commencement date’). Right-of-use assets are initially 
measured at cost, including the amount of the initial measurement of the lease liability, adjusted for lease 
payments on or after the commencement date, plus initial direct costs incurred and an estimate of all of the costs 
for dismantling and removing the underlying asset, less any lease incentives received, including deferred rent. 
The right-of-use asset is subsequently measured at cost less accumulated depreciation and accumulated 
impairment losses. The depreciation is recognised in a manner consistent with existing standards for property, 
plant and equipment over the lease term. 
Lease liabilities are initially measured at the present value of the lease payments over the lease term. The lease 
payments are discounted using the Company’s incremental borrowing rate. The lease liability is subsequently 
measured by increasing the carrying amount to reflect interest on the lease liability and reducing the carrying 
amount to reflect the lease payments made.  
The interest expense relating to lease liabilities is recognised in profit or loss using the effective interest method. 
 
New right-of-use assets and lease liabilities are non-cash transactions and thus excluded from the consolidated 
statement of cash flows. 
The Company as a lessor: 
As part of its normal business activity, the Company enters into lease contracts whereby gas generation 
technologies are manufactured and placed at customer premises in order for the customer to have on-demand gas 
supply (Gas-as-a-Service). Depending on the lease contracts, the Company either classifies the leases as operating 
or finance leases.  
To classify each lease, the Company makes an overall assessment of whether the lease transfers to the lessee 
substantially all of the risks and rewards of ownership incidental to ownership of the underlying asset. If this is 
the case, the lease is classified as finance lease, if not, the lease is classified as an operating lease. As part of this 
assessment, the Company considers certain indicators such as whether the lease term is for the majority of the 
economic life of the assets.  
 
If an arrangement contains lease and non-lease components, the Company applies IFRS 15 to allocate the 
consideration in the lease arrangement.  
Income from operating lease contracts is recognised on a straight-line basis over the term of the lease and is 
presented in the consolidated statement of profit or loss under revenue. 
Amounts due from lessees under finance leases are recognised at the amount of the Company’s net investment in 
the leases (finance leases receivables). Finance lease income, presented within finance income, is allocated to 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(13) 
 
accounting periods to reflect a constant periodic rate of return on the Company’s net investment outstanding in 
respect of the leases.  
Subsequent to initial recognition, the Company reviews the estimated unguaranteed residual value and applies the 
expected credit loss model to recognise a provision on its finance lease receivables.  
Long-term incentive plan 
The Company accounts for stock options using the fair value method. Each tranche in an award is considered a 
separate award with its own vesting year and grant date fair value. Fair value of each tranche is measured at the 
date of grant using the Black-Scholes option pricing model. The Black-Scholes model was developed to estimate 
the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, this model 
usually requires the input of assumptions, including expected stock price volatility. For options granted to 
directors, officers and employees of the Company, compensation expense is recognized over the tranche’s vesting 
period by increasing contributed surplus based on the number of awards expected to vest. The number of awards 
expected to vest is reviewed at least annually. For options granted to non-employees, the transaction is measured 
with reference to the fair value of the goods or services when received. Related expense is recognized over the 
period during which the goods or services from the non-employees are received. 
 
A corresponding increase is recorded in contributed surplus when stock options are expensed. When stock options 
are exercised, share capital is credited by the sum of the consideration paid and the related amount previously 
recorded in contributed surplus.  
The cost of the restricted share units (RSUs) is measured at the fair value of the common shares of the Company 
at the grant date and the number of RSUs expected to vest. The cost is recognized as compensation expense in 
the statement of income (loss) from the date of grant on a straight-line basis over the 36-month vesting period 
with a corresponding increase in equity. The Company revises the estimate of the number of RSUs expected to 
vest, if subsequent information indicates that the number of RSUs expected to vest differs from previous 
estimates. 
The cost of deferred share units (DSUs) is measured at the fair value of the common shares of the Company at 
the grant date and the number of DSUs expected to vest. The cost is gradually recognized as compensation 
expense in the statement of income (loss) from the date of grant over a progressive vesting period based on the 
remaining vesting period with a corresponding increase in equity. The Company revises the estimate of the 
number of DSUs expected to vest when necessary, if subsequent information indicates that the number of DSUs 
expected to vest differs from previous estimates. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(14) 
 
Research and development expenses 
Research expenses are charged to expenses as incurred. Development expenses are charged to expenses as 
incurred unless they meet criteria for deferral and amortization. There were no development expenses capitalised 
during the year ended December 31, 2021 and 2020.  
Income taxes 
Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of income 
(loss) except to the extent that it relates to items recognized directly in other comprehensive income or equity, in 
which case the income tax is also recognized directly as such. 
Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or 
substantively enacted at the end of the reporting year, and any adjustment to tax payable in respect of previous 
years. 
In general, deferred income tax is recognized in respect of temporary differences arising between the tax bases of 
assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is 
determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at 
the statement of financial position date and are expected to apply when the deferred tax asset or liability is settled. 
Deferred income tax assets are recognized to the extent that it is probable that the assets can be recovered. 
 
Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, 
except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable 
that the temporary difference will not reverse in the foreseeable future. 
Deferred income tax assets and liabilities are presented as non-current. 
Foreign currency translation 
Functional and presentation currency: 
Items included in the financial statements of each entity consolidated in the Company group are measured using 
the currency of the primary economic environment in which the entity operates (the functional currency). The 
consolidated financial statements are presented in Canadian dollars, which is the Company’s functional currency. 
The financial statements of entities that have a functional currency different from that of the Company (foreign 
operations) are translated into Canadian dollars as follows: assets and liabilities – at the closing rate at the date of 
the statement of financial position, and income and expenses – at the average rate of the year. All resulting changes 
are recognized in other comprehensive income (loss) as cumulative translation adjustment. 
When an entity disposes of its entire interest in a foreign operation, or loses control, joint control or significant 
influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive 
income (loss) related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(15) 
 
interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or 
losses accumulated in other comprehensive income (loss) related to the subsidiary is reallocated between 
controlling and non-controlling interests. 
Transactions and balances: 
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at 
the dates of the transactions. Generally, foreign exchange gains and losses resulting from the settlement of foreign 
currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities 
denominated in currencies other than an operation’s functional currency are recognized in the consolidated 
statement of income (loss). 
Recently issued accounting standards  
Standards, amendments and interpretations to existing standards that are not yet effective and have not been 
adopted early by the Company 
At the date of authorisation of these consolidated financial statements, several new, but not yet effective, standards 
and amendments to existing standards, and interpretations have been published by the IASB. None of these 
standards or amendments to existing standards have been adopted early by the Company. Management anticipates 
that all relevant pronouncements will be adopted for the first period beginning on or after the effective date of the 
pronouncement. New standards, amendments and interpretations not adopted in the current year have not been 
disclosed as they are not expected to have a material impact on the Company’s consolidated financial statements. 
Significant accounting judgments and estimation uncertainties 
Critical accounting estimates and judgements 
The Company makes estimates and assumptions concerning the future that will, by definition, seldom equal actual 
results. The following are the estimates and judgments applied by management that affect the Company’s 
consolidated financial statements. 
i. 
Inventories must be valued at the lower of cost and net realizable value. 
 
A write-down of inventory will occur when its estimated market value less applicable variable selling 
expenses is below its carrying amount. Materials and other supplies held for use in the production of 
inventories are not written down below cost if the finished products in which they will be incorporated 
are expected to be sold at or above cost. This estimation process involves significant management 
judgment and is based on the Company’s assessment of market conditions for its products determined by 
historical usage, estimated future demand and, in some cases, the specific risk of loss on specifically 
identified inventory. Any change in the assumptions used in assessing this valuation will impact the 
carrying amount of the inventory and have a corresponding impact on cost of goods sold. 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(16) 
 
ii. Impairment of internally generated intangible assets 
 
The Company performs a test for internally generated intangible assets impairment when there is any 
indication that internally generated intangible assets have suffered any impairment in accordance with 
the accounting policy stated in the summary of significant accounting policies of these consolidated 
financial statements. The recoverable amounts of internally generated intangible assets have been 
determined based on value-in-use calculations. The value-in-use calculation is based on a discounted cash 
flow model. These calculations require the use of estimates and forecasts of future cash flows. Qualitative 
factors, including the degree of variability in cash flows as well as other factors are considered when 
making assumptions with regard to future cash flows and the appropriate discount rate. A change in any 
of the significant assumptions or estimates used to evaluate internally generated intangible assets could 
result in a material change to the results of operations. 
 
iii. Percentage of completion and revenues from long-term production-type contracts 
 
Revenues recognized on long-term production-type contracts reflect management’s best assessment by 
taking into consideration all information available at the reporting date and the result on each ongoing 
contract and its estimated costs. Management assesses the profitability of the contract by applying 
important judgments regarding milestones marked, actual work performed and estimated costs to 
complete. Actual results could differ because of unforeseen changes in the ongoing contracts’ models. 
 
iv. Allowance for expected credit loss 
 
The Company recognizes the impairment of financial assets in the amount of expected credit losses by 
means of the simplified approach, measuring impairment losses as lifetime expected credit losses. The 
trade receivables have been assessed on a collective basis as they possess shared credit risk characteristics 
and have been grouped based on the days past due.   
 
v. Acquisition valuation method 
 
The Company uses valuation techniques when determining the fair value of certain assets and liabilities 
acquired in a business combination. In particular, the fair values of the intangible assets, goodwill and 
contingent consideration are dependent on the outcome of many variables including the acquirees’ future 
profitability. 
 
vi. Leases 
 
Recognizing leases requires judgment and use of estimates and assumptions. Judgement is used to 
determine whether there is reasonable certainty that a lease extension or cancellation option will be 
exercised. Furthermore, management estimates are used to determine the lease terms and the appropriate 
interest rate to establish the lease liability.  
 
Classification of finance and operating leases requires management to make assumptions related to the 
economic life and the fair value of the leased asset. In addition, at the commencement date of finance 
leases, the measurement of selling profit requires assumptions such as the determination of the 
unguaranteed residual value, the fair value of the leased asset and the rate implicit in the lease. Those 
assumptions are based on management’s best estimate by considering all information available at the 
reporting date, including profit margins by reference to transactions involving assets of a similar nature, 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(17) 
 
market funding rates, the economic life of assets of a similar nature and the expected value of the asset at 
the end of the lease.  
 
vii. Impairment of non-financial assets and goodwill 
 
In assessing impairment, management estimates the recoverable amounts of each asset or cash-generating 
unit based on expected future cash flows and uses an interest rate to discount them. Estimation uncertainty 
relates to assumptions about future operating results and the determination of a suitable discount rate. 
 
2 
Business combinations   
Acquisitions of 2021 
Inmatec 
On February 22, 2021, the Company acquired 100% of Inmatec Gase Technologie GmbH & Co. KG, Inmatec 
GmbH and Inmatec Gas Technology FZC RAK (collectively “Inmatec”) in the United Arab Emirates for an 
aggregate cash consideration of $36,704.  
Founded in 1993, Inmatec is an international market leader in the production of nitrogen and oxygen generators. 
Designed, developed and produced in Germany, over 8,000 Inmatec systems have been deployed and sold around 
the world. Its German manufacturing and engineering capabilities have resulted in a reputation for high quality 
and extremely reliable products. Inmatec’s products and manufacturing are among the best-in-class and this 
acquisition gives Xebec an accelerated entry into offering these products in North America.  
Goodwill is not expected to be deductible for tax purposes and is included in the Systems segment.  
Nortec  
On April 30, 2021, the Company acquired all of the outstanding shares of Tennessee based Nortekbelair 
Corporation (“Nortec”) for a purchase price of $8,794 through a combination of cash on hand, of which $4,461 
was paid in cash on closing, and 735,838 common shares of Xebec issued to the seller at a fair value of $4.33 per 
share, the closing price of Xebec’s shares on April 30, 2021. The purchase agreement includes an additional 
contingent consideration of $1,147 payable based on achievement of sales targets over the next three years. 
Nortec was founded in 2008 based on three key pillars of performance: quality, perfection and innovation. 
Although the company was founded in 2008, Nortec’s origins in the compressed air industry go back several 
decades. Nortec specializes in compressed air drying and industrial systems, and the company’s systems are used 
in a broad spectrum of applications, ranging from small shops to major manufacturing plants. Nortec’s principal 
has remained with the Company after the acquisition and continues his focus on R&D and product development 
within the Company.  
Goodwill is expected to be deductible for tax purposes and is included in the Support segment. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(18) 
 
Tiger 
On June 11, 2021, the Company acquired all of the outstanding shares of United Kingdom based Tiger Filtration 
Limited (“Tiger”) for a total consideration of $20,070 subject to certain holdbacks and adjustments. The purchase 
agreement includes an additional contingent consideration of $2,112 payable based on achievement of sales 
targets over the next two years. 
Established in 2004, Tiger Filtration was an independently owned British based company specialising in the 
manufacture of high-quality alternative in-line filter elements, vacuum pump separators, compressor air & oil 
separators, high-pressure stainless-steel filter housings and bespoke filtration solutions. Tiger’s products are 
supplied from a 14,000 sq. ft. facility in Sunderland, UK and sold globally to customers ranging from small 
businesses to international organisations who expect quality products and an exceptional level of service. Two of 
its principals retired and one remains with Tiger as Managing Director and continue his leadership in sales and 
business development. This acquisition will provide the Company with a profitable and recurring aftermarket 
manufacturing business for elements and filters. Goodwill is not expected to be deductible for tax purposes and 
is included in the Support segment. 
California Compression, LLC 
On August 26, 2021, the Company acquired the securities of California Compression, LLC for a total 
consideration of $9,220 of which $7,539 was paid in cash on closing, and 382,718 common shares of Xebec 
issued to the seller at a fair value of $3.32 per share, the closing price of Xebec’s shares on that day.  
Founded in 1975, California Compression, LLC is one of the largest compressed air distributors in Northern 
California. California Compression, LLC gives Xebec distribution facilities for customers located in the Northern 
California of the United States.  
Goodwill is expected to be deductible for tax purposes and is included in the Support segment. 
Wisconsin Compressed Air 
On September 1, 2021, the Company acquired the assets of Wisconsin Compressed Air for an aggregate cash 
consideration of $2,303 including a balance of acquisition payable of $448.  
Founded in 1976, Wisconsin Compressed Air has been supplying customers with high-quality compressed air 
products from the industry’s top manufacturers.  Wisconsin Compressed Air services gives Xebec maintenance 
services capacities to customers located in the North Central region of the United States.  
Goodwill is expected to be deductible for tax purposes and is included in the Support segment. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(19) 
 
UEC, LLC 
On November 3, 2021, the Company acquired Colorado-based UECompression (“UEC”) for a total consideration 
of $10,321 subject to certain holdbacks and adjustments.  
Founded in 1983, UEC is a premier designer and builder of custom air and gas compressor solutions for power 
generation, industrial and energy applications. The acquisition of UEC provides the Company with a cost-
effective and timely pathway towards expanding production capacity for standardized renewable gas systems.  
Goodwill is expected to be deductible for tax purposes and is included in the Support segment. 
The determination of the fair value of the assets acquired and liabilities assumed arising from the acquisitions are 
as follows: 
 
The fair value of trade and other receivables acquired as part of the business acquisitions amounted to $17,016 
with the same gross contractual amount. As at the acquisition dates, the Company’s best estimate of the 
contractual cash flows not expected to be collected amounted to $263. 
The earnout payments relate to contractual acquisition price adjustments base on determined specific factors for 
previous years acquisitions. 
Total acquisition costs incurred during fiscal 2021 and 2020 relating to these acquisitions are included in other 
gains and losses in the consolidated statement of loss (Note 4). 
Inmatec
Nortec
Tiger
California 
Compression
Wisconsin 
Compressed 
Air
UEC
Prior Year 
earnout 
payments
Total
Recognized amounts of identifiable net assets
Trade and other receivables
3,108
          
1,428
       
821
             
2,143
                  
421
                     
8,832
                  
-
                        
16,753
                 
Inventories
4,454
          
610
           
307
             
859
                     
565
                     
1,711
                  
-
                        
8,506
                   
Other current assets
64
                
-
            
-
              
35
                        
6
                          
174
                     
-
                        
279
                       
Total current assets
7,626
          
2,038
       
1,128
          
3,037
                  
992
                     
10,717
               
-
                        
25,538
                 
Property, plant and equipment
1,415
          
29
             
285
             
1,379
                  
566
                     
5,540
                  
-
                        
9,214
                   
Intangibles
30,354
       
1,966
       
-
              
-
                      
-
                      
65
                        
-
                        
32,385
                 
Total non-current assets
31,769
       
1,995
       
285
             
1,379
                  
566
                     
5,605
                  
-
                        
41,599
                 
Trade, other payables and accrued liabilities
(3,342)
        
(228)
         
(1,096)
        
(2,403)
                
(126)
                    
(7,801)
                
-
                        
(14,996)
               
Contract liabilities
(1,242)
        
-
            
-
              
(215)
                    
(42)
                      
(3,716)
                
-
                        
(5,215)
                  
Warranty provision
(1,426)
        
-
            
-
              
-
                      
-
                      
(1,305)
                
(2,731)
                  
Total current liabilities
(6,010)
        
(228)
         
(1,096)
        
(2,618)
                
(168)
                    
(12,822)
              
-
                        
(22,942)
               
Future income taxes
(7,303)
        
(7,303)
                  
Long-term debt
(3,443)
        
-
            
(284)
            
(963)
                    
(669)
                    
(3,565)
                
-
                        
(8,924)
                  
Total non-current liabilities
(10,746)
      
-
            
(284)
            
(963)
                    
(669)
                    
(3,565)
                
-
                        
(16,227)
               
Identifiable net assets
22,639
       
3,805
       
33
                
835
                     
721
                     
(65)
                      
-
                        
27,968
                 
Goodwill on acquisition
11,356
       
4,862
       
19,516
       
7,130
                  
1,582
                  
9,691
                  
-
                        
54,137
                 
Total assets acquired
33,995
       
8,667
       
19,549
       
7,965
                  
2,303
                  
9,626
                  
-
                        
82,105
                 
Cash and Cash equivalent at acquisition
2,709
          
127
           
521
             
1,255
                  
-
                      
695
                     
5,307
                   
Total purchase consideration
36,704
       
8,794
       
20,070
       
9,220
                  
2,303
                  
10,321
               
-
                        
87,412
                 
Fair value of shares issued
-
              
3,186
       
-
              
1,271
                  
-
                      
-
                      
-
                        
4,457
                   
Fair value of contingent consideration
-
              
1,147
       
2,112
          
-
                      
-
                      
-
                      
-
                        
3,259
                   
Restricted cash and balance of acquisition payable 
-
              
-
            
-
              
410
                     
448
                     
6,169
                  
-
                        
7,027
                   
Earnout payments to prior year acquisitions
-
              
-
            
-
              
-
                      
-
                      
-
                      
(4,121)
                  
(4,121)
                  
Total cash consideration paid at aquisition date
36,704
       
4,461
       
17,958
       
7,539
                  
1,855
                  
4,152
                  
4,121
                   
76,790
                 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(20) 
 
As at December 31, 2021, the purchase price allocation of Nortec is final and those of Inmatec, Tiger, California 
Compression, XBC Flow Services and UEC are preliminary. 
Acquisitions of 2020 
HyGear Technology and Services B.V. 
On December 31, 2020, the Company acquired 100% of Green Vision Holding B.V., the parent company of 
HyGear Technology and Services B.V. (“HyGear”) for aggregate consideration of $156,520, consisting of a cash 
payment of $66,391 and 10,014,364 shares issued at a fair value of $9.00 per share, the closing price of Xebec’s 
shares on December 31, 2020. HyGear is an emerging developer, manufacturer, and supplier of technology and 
products for the production, recovery, purification, and mixing of industrial gases, such as hydrogen and nitrogen. 
HyGear’s technological backbone consists of a number of active patents issued both in EU countries and the 
United States.  
The cash consideration for the acquisition was financed using the proceeds from the Corporation’s bought deal 
public offering of subscription receipts completed through a syndicate of underwriters, and from a concurrent 
private placement of subscription receipts, through which combined gross proceeds of $143,752 were raised. Both 
the bought deal public offering and the private placement closed on December 30, 2020. 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(21) 
 
The financial position as at December 31, 2020 as been restated according to the final purchase price allocation 
at the acquisition date and is as follows:  
  
As 
disclosed 
in 
FY2020 
Adjustment 
  
Restated 
presentation 
Recognized amounts of 
identifiable net assets 
  
  
  
  
Trade and other receivables 
5,905  
- 
5,905 
Inventories 
2,059  
(280) 
1,779 
Other current assets 
129  
- 
129 
Total current assets 
8,093  
(280) 
  
7,813 
Property, plant and equipment 
27,884  
(215) 
  
27,669 
Right of use assets 
3,104 
610 
 
3,714 
Intangibles 
4,252 
52,599 
 
56,851 
Other non-current assets 
3,016  
- 
  
3,016 
Total non-current assets 
38,256  
52,994 
91,250 
Trade, other payables and 
accrued liabilities 
(4,353) 
(334) 
(4,687) 
Contract liabilities 
(2,941) 
- 
 
(2,941) 
Current portion of long-term debt 
(4,281) 
(148) 
(4,429) 
Total current liabilities 
(11,575) 
(482) 
(12,057) 
Deferred income tax liability 
(350) 
(13,834) 
 
(14,184) 
Long-term debt 
(31,801) 
(182) 
  
(31,983) 
Total non-current liabilities 
(32,151) 
(14,016) 
  
(46,167) 
Identifiable net assets 
2,623  
38,216 
  
40,839 
Goodwill on acquisition 
151,759  
(44,961) 
  
106,798 
Total assets acquired 
154,382  
(6,745) 
  
147,637 
Cash and cash equivalents 
acquired 
2,138  
- 
  
2,138 
Total purchase consideration 
156,520  
(6,745) 
 
149,775 
Fair value of shares issued 
90,129   
(6,745) 
  
83,384 
Restricted cash and balance of 
acquisition payable  
6,555  
- 
  
6,555 
Total cash consideration paid at 
acquisition date 
59,836  
- 
  
59,836 
 
Enerphase Industrial Solutions Inc. (Air Flow) 
On July 31, 2020, the Company acquired all of the outstanding securities of Enerphase Industrial Solutions Inc. 
(doing business as “Air Flow”) for a purchase price of $5,781. The purchase agreement includes an additional 
contingent consideration over the three years following acquisition.  
Air Flow is a leading distributor and service provider of compressed air equipment in North Carolina. Incorporated 
in 1981, the company brings decades of industry experience, has built longstanding relationships with major 
manufacturers, and has developed a significant service footprint through numerous equipment installations. Air 
Flow’s focus is on preventative maintenance solutions, air energy system audits and analysis, timely machine 
rentals, and parts and service.  
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(22) 
 
Applied Compression Systems Ltd.  
On August 31, 2020, the Company acquired all outstanding shares of Applied Compression Systems Ltd. (“ACS”) 
for a purchase price of $4,828 which includes an amount of $778 that was paid on January 19, 2021. Deferred 
compensation will be payable for a period of three years as agreed by both parties following acquisition.  
Applied Compression Systems Ltd., located in British Colombia, offers a single source solution for air & gas 
compression requirements. The company has a strong focus on custom designed and fabricated compressor 
packages for specialized applications in the oil, gas, petrochemical, alternative fuel, waste-to-energy, research, 
power generation, mining and manufacturing industries. ACS can supply either standard units or design and 
fabricate equipment that is custom-built to specific requirements from concept to completion. 
The Titus Company 
On October 30, 2020, the Company acquired all the outstanding shares of “The Titus Company” (“Titus”) for a 
purchase price of $8,236. The purchase agreement includes an amount of $840,000 USD (par value $1,000,000 
USD) which will be payable over a three years period following acquisition.  
Founded in 1986 in Pennsylvania, Titus has been in partnership with large and small companies throughout the 
Eastern Pennsylvania, Delaware and New Jersey regions and provides superior expertise and the capability to 
serve a wide range of needs. The Titus Company is also the largest supplier of air dryers to the United States 
Navy. With this acquisition, Xebec’s Cleantech Service Network (CSN) coverage expanded to include Eastern 
Pennsylvania, Delaware and New Jersey. 
Goodwill is not expected to be deductible for tax purposes and is included in the Systems segment.  
3 
Segmented information 
The Company operates three business segments and specializes in Systems (Cleantech), Support (Industrial Air 
and Gas Products, Parts, Service and Operational Support) and Corporate. 
The profitability measure employed by the Company for making decision about allocating resources to segments 
and assessing segment performance is adjusted segment income.  Adjusted segment income is a non IFRS measure 
calculated by taking operating income and excluding depreciation, amortization, integration and acquisition costs 
and other gains and losses arising from significant transactions or material events, which gives an indication of 
the profitability of each segment excluding the impact of items not specifically related to the segment’s ongoing 
performance.  
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(23) 
 
Income (loss) summarized by business segments are as follows: 
 
 
Systems 
 
Support 
 
Corporate 
 
Total 
 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
Revenues 
67,827 
28,100 
58,074 
28,420 
- 
- 
125,901 
56,520 
Gross Margin 
9,262 
(7,347) 
20,242 
7,613 
- 
- 
29,504 
266 
Gross Margin % 
14% 
(26%) 
35% 
27% 
- 
- 
23% 
0.5% 
Depreciation and 
amortization 
9,852 
2,595 
2,314 
1,190 
- 
- 
12,166 
3,785 
Segment income 
(2,878) 
(10,367) 
8,238 
2,399 
(28,810) 
(23,999) 
(23,450) 
(31,967) 
Adjusted Segment income 
6,950 
(7,661) 
10,551 
3,627 
(26,319) 
(17,962) 
(8,818) 
(21,996) 
 
Reconciliation of adjusted segment income is as follows: 
 
 
Systems 
 
Support 
 
Corporate 
 
Total 
 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
2021 
$ 
2020 
$ 
Segment income 
(2,878) 
(10,367) 
8,238 
2,399 
(28,810) 
(23,999) 
(23,450) 
(31,967) 
Depreciation and 
amortization 
9,852 
2,595 
2,314 
1,190 
- 
- 
12,166 
3,785 
Net finance expense 
- 
- 
- 
- 
6,484 
2,749 
6,484 
2,749 
Income taxes 
- 
- 
- 
- 
2,570 
(9) 
2,570 
(9) 
Other (gains) and losses 
(24) 
111 
(1) 
38 
(6,563) 
3,297 
(6,588) 
3,446 
Adjusted Segment income 
6,950 
(7,661) 
10,551 
3,627 
(26,319) 
(17,962) 
(8,818) 
(21,996) 
 
 
For the year ended December 31, revenue summarized by country, as determined by location of the customers, is 
as follows: 
 
2021 
$ 
2020 
$ 
United States                                                                
59,056 
26,647 
Germany                                                                
25,395 
- 
Canada 
21,251 
14,572 
China  
4,668 
13,510 
Other 
15,531 
1,791 
Total Revenues 
125,901 
56,520 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(24) 
 
 
No single customer contributed more than 10% to the Company’s revenue in 2021 (none in 2020). 
The location of the Company’s non-current assets by geographic region are as follows: 
 
2021 
$ 
2020 
$ 
Canada 
178,333 
174,329 
Europe 
120,357 
34,202 
United States 
30,659 
17,827 
Asia 
- 
229 
Total Non-Current assets 
329,349 
226,587 
 
4 
Other (gains) and losses 
 
 
2021 
$ 
2020 
$ 
Foreign exchange loss (gain) 
 (296) 
103 
Loss (gain) on disposal of assets 
6 
- 
Loss (gain) on conversion of shares issued by a subsidiary 
 (45) 
217 
Remeasurement of investment (note 25) 
(21,122) 
- 
Integration and acquisition costs 
 5,206 
6,160 
Impairment charge of intangible assets 
 8 
- 
One-time payment arising from the prior departure of employees 
6,058 
- 
Miscellaneous other (gains) and losses 
1,391 
- 
Other (gains) and losses 
(8,794) 
6,480 
 
For the year ended December 31, 2021, costs related to acquisitions amounted to $3,159 (2020 – $5,728). 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(25) 
 
5 
Net finance expenses 
 
2021 
$ 
2020 
$ 
Accretion of the obligation arising from shares issued by a subsidiary 
120 
306 
Financing fees 
746 
492 
Interest and bank charges 
914 
460 
Guarantee letter fees 
82 
243 
Interest on debt 
4,971 
1,570 
Accretion and revaluation of government royalty program obligation (Note 17) 
14 
20 
Penalties 
676 
- 
Finance income 
(1,039) 
(343) 
 
6,484 
2,749 
 
6 
Income taxes  
The reconciliation of income taxes, computed at the Canadian statutory rates to income tax recovery is as follows: 
 
 
2021 
$ 
2020 
$ 
Loss before income taxes 
(20,880) 
(31,967) 
Canadian statutory tax rate 
26.5% 
26.5% 
Expected income tax recovery 
(5,533) 
(8,471) 
Increase (decrease) in income taxes resulting from: 
 
 
     Temporary difference unrecognized (recognized) 
9,649 
6,962 
     Difference in foreign tax rate 
179 
184 
     Stock base compensation 
792 
279 
     Deconsolidation of corporation in China 
(5,027) 
- 
     Foreign exchange on consolidation 
- 
- 
     Non-deductible acquisition costs 
(889) 
985 
     Tax assets recognized 
- 
- 
     True up and other 
3,399 
52 
 
2,570 
(9) 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(26) 
 
Composition of current income taxes in the income statement is as follows: 
 
2021 
$ 
2020 
$ 
Inception and reversal of temporary differences 
936 
421 
 
936 
421 
 
Composition of deferred income taxes in the Consolidated Statement of Loss is as follows: 
 
2021 
$ 
2020 
$ 
Inception and reversal of temporary differences 
(8,090) 
(7,392) 
Temporary difference not recorded 
9,649 
6,962 
Change in deferred tax rate 
- 
- 
 
1,559 
(430) 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(27) 
 
Movement of deferred income tax in 2021 is as follows: 
 
 
 
 
 
 
 
 
 
Property, 
plant and 
equipment 
$ 
Intangible 
assets 
 
$ 
Debentures 
 
 
$ 
Government 
royalty 
program 
$ 
Non-
capital 
losses 
$ 
Others 
 
 
$ 
Deferred 
tax 
liability 
$ 
Balance as at December 31, 2019 
- 
(203) 
- 
(10) 
44 
(34) 
(203) 
P&L 
52 
164 
- 
(9) 
- 
223 
430 
Business acquisition 
(39) 
(16,041) 
- 
- 
- 
(629) 
(16,709) 
Equity Component 
- 
60 
- 
- 
- 
12 
72 
Balance as at December 31, 2020 
13 
(16,020) 
- 
(19) 
44 
(428) 
(16,410) 
P&L 
264 
(1,174) 
- 
14 
1,670 
(2,331) 
(1,557) 
Business acquisition 
- 
(6,268) 
- 
- 
- 
- 
(6,268) 
Capital 
- 
- 
- 
- 
- 
- 
- 
Equity Component 
- 
- 
- 
- 
- 
- 
- 
Balance as at December 31, 2021 
277 
(23,462) 
- 
(5) 
1,714 
(2,759) 
(24,235) 
 
As at December 31, 2021, deductible timing differences for which the company has not recognized deferred tax 
assets are as follows: 
 
Federal 
$ 
Provincial 
$ 
China 
$ 
USA 
$ 
Italy 
$ 
Netherlands 
$ 
Property and equipment 
1,890 
1,878 
- 
- 
- 
- 
Scientific research and development 
expenses 
25,433 
25,480 
- 
- 
- 
- 
Capital losses carried forward 
219 
219 
- 
- 
- 
- 
Operating losses carried forward 
107,348 
109,209 
4,467 
- 
5,179 
5,880 
Other 
15,083 
15,083 
1,221 
- 
- 
- 
 
149,973 
151,869 
5,688 
- 
5,179 
5,880 
 
As at December 31, 2020, deductible timing differences for which the company has not recognized deferred tax 
assets are as follows: 
 
Federal 
$ 
Provincial 
$ 
China 
$ 
USA 
$ 
Italy 
$ 
Netherlands 
$ 
Property and equipment 
1,453 
1,440 
- 
- 
- 
- 
Scientific research and development 
expenses 
25,433 
25,480 
- 
- 
- 
- 
Capital losses carried forward 
219 
219 
- 
- 
- 
- 
Operating losses carried forward 
80,591 
82,485 
260 
1,675 
4,109 
5,880 
Other 
13,777 
13,777 
1,221 
- 
- 
- 
 
121,473 
123,401 
1,481 
1,675 
4,109 
5,880 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(28) 
 
The ability to realize tax benefits is dependent upon a number of factors, including the future profitability of 
operations.  Deferred tax assets are recognized only to the extent that it is probable that sufficient taxable profits 
will be available to allow the asset to be recovered. Accordingly, some deferred tax assets have not been 
recognized. Deferred tax assets not recognized equal an amount of $43,525 (2020 – $35,587). 
As at December 31, 2021, the Company has non-capital tax losses, which are available to reduce income taxes in 
future years and expire as follows: 
 
Federal 
$ 
Provincial 
$ 
China 
$ 
USA 
$ 
Italy 
$ 
Netherlands 
$ 
2022-2026 
14,128 
13,438 
4,467 
- 
- 
- 
2027-2041 
93,230 
95,781 
- 
96 
- 
- 
Indefinite 
- 
- 
- 
4,247 
5,179 
- 
 
107,3581 
109,219 
260 
4,343 
4,109 
- 
The Company has scientific research and experimental development expenses of $25,433 (2020 - $28,433) which 
are available to be carried forward indefinitely and deducted against future tax income otherwise calculated. The 
potential benefit has not been recorded in the financial statements. 
7 
Share Capital 
Authorized and issued shares 
The Company is incorporated under the Canada Business Corporations Act, and its authorized share capital 
consists of an unlimited number of common shares, without par value. 
Issuance of common shares 
On June 26, 2020, the Company closed a bought deal public offering from which a total of 7,986,750 common 
shares of Xebec were sold at a price of $3.60 per common share for aggregate gross proceeds of $28,752. 
 
On December 30, 2020, the Company closed an upsized bought deal public offering of 24,784,800 subscription 
receipts at a price of $5.80 per Subscription Receipt for gross proceeds of $143,752. Following the acquisition of 
HyGear, the subscription receipts were converted into common shares on December 31, 2020 and issued on 
January 4, 2021. 
On December 30, 2020, the Company closed an upsized concurrent private placement of 10,905,174 subscription 
receipts for gross proceeds of $63,250. Following the acquisition of HyGear, the subscription receipts were 
converted into common shares on December 31, 2020 and issued on January 4, 2021. The total issuance costs 
amounted to $12,194. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(29) 
 
On December 31, 2020, the Company issued 10,014,364 common shares at fair value of $9.00 per share, the 
closing price of Xebec’s shares on December 31, 2020, to acquire 100% of Green Vision Holding B.V., the parent 
company of HyGear Technology and Services B.V. for aggregate consideration of $90,129. 
On April 30, 2021, the Company issued 735,838 common shares at a fair value of $4.33 per share, the closing 
price of Xebec’s shares on April 30, 2021, for aggregate gross consideration of $3,186 to acquire all of the 
outstanding shares of Tennessee based Nortekbelair Corporation. 
On August 26, 2021, the Company issued 382,718 common shares at a fair value of $3.32 per share for aggregate 
consideration of $1,271 to acquire the securities of California Compression, LLC. 
On October 5, 2021, the Company issued 735,294 common shares at a fair value of $2.72 per share for aggregate 
consideration of $2,000 for payment arising from the prior departure of employees. 
Warrants and compensation shares 
On June 26, 2020, the Company closed a bought deal public offering from which a total of 479,205 compensation 
options (more fully described below) were issued. The issuance costs, excluding the non-transferable options to 
the agents, were $2,315. The fair value of the 479,205 compensation options was $631, which was estimated 
using the Black Scholes Option Pricing Model with the following assumptions: 
Risk-free interest rate 
 
0.28% 
Annualized volatility 1  
 
74.88% 
Share price 
 
$3.60 
Expected life of compensation options 
 
1 year 
 
In connection with the Offering, the Corporation paid the Underwriters a cash commission equal to 6% of the 
gross proceeds of the Offering, and compensation options equal to 6% of the common shares issued pursuant to 
the Offering. Each compensation option entitled the Underwriters to purchase a common share at an exercise 
price of $3.60 for a period of 12 months from the closing date of the Offering. 
 
 
 
1 The expected volatility used was based in the historic volatility of the Company’s share price 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(30) 
 
On May 5, 2020, the Company entered into a loan agreement for an unsecured loan facility of $10 million and 
providing 3,000,000 warrants at an exercise price of $4.58 for a two-year term. The fair value of the warrants was 
$2,954, which was estimated using the Black Scholes Option Pricing Model with the following assumptions: 
Risk-free interest rate 
 
1.11% 
Annualized volatility 1  
 
70.33% 
Share price 
 
$3.35 
Expected life of compensation options 
 
2 years 
 
On November 9, 2021, the Company entered into an amended and restated Loan Agreement, increasing the credit 
facility provided by $15.0 million and providing for the issuance of 4,500,000 warrants at an exercise price of 
$4.44 per warrant for a three-year term. The fair value of the warrants was $6,986, which was estimated using the 
Black Scholes Option Pricing Model with the following assumptions: 
Risk-free interest rate 
 
0.89% 
Annualized volatility 1  
 
70.1% 
Share price 
 
$3.73 
Expected life of compensation options 
 
3 years 
 
As at December 31, 2021, compensation options, compensation warrants and warrants are as follows: 
 
 
 
 
 
 
 
 
Description 
Expiry 
date 
Exercise 
Price 
Beginning 
balance 
Issued 
 
Cancelled 
Exercised 
Balance 
end of 
year 
Compensation 
Options 
June-21 
$3.60 
418,267 
- 
- 
(418,267) 
- 
Warrants  
May-22 
$4.58 
3,000,000 
- 
- 
- 
3,000,000 
Warrants 
Nov-24 
$4.44 
- 
4,500,000 
- 
- 
4,500,000 
  
  
$4.50  
3,418,267  
4,500,000  
-  
(418,267) 
7,500,000 
 
The average share price for the exercised options was $5.05. 
 
1 The expected volatility used was based in the historic volatility of the Company’s share price  

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(31) 
 
As at December 31, 2020, compensation options, compensation warrants and warrants are as follows: 
 
 
 
 
 
 
 
 
Description 
Expiry 
date 
Exercise 
Price 
Beginning 
balance 
Issued 
 
Cancelled 
Exercised 
Balance 
end of 
year 
Warrants 
May-20 
$1.05  
2,543,931  
- 
- 
(2,543,931) 
- 
Compensation 
Options 
May-20 
$0.75  
4,800  
- 
- 
(4,800) 
- 
Warrants 
Jul-20 
$1.85  
8,272,857  
-  
(14,356)  
(8,258,501) 
- 
Compensation 
Options 
Jul-20 
$1.40  
347,760  
-  
-  
(347,760) 
- 
Compensation 
warrants 
Jul-20 
$1.85  
149,040  
347,760  
-  
(496,800) 
- 
Compensation 
Options 
Dec-20 
$2.10  
657,156  
-  
-  
(657,156) 
- 
Compensation 
Options 
June-21 
$3.60 
- 
479,207 
- 
(60,940) 
418,267 
Warrants  
May-22 
$4.58 
- 
3,000,000 
- 
- 
3,000,000 
  
  
$4.46  
11,975,544  
3,826,965  
(14,356)  
(12,369,888) 
3,418,267 
 
Income (loss) per share 
The denominators for the basic and diluted earnings per share computation are as follows: 
 
2021 
2020 
Weighted average number of common shares outstanding 
153,471,109 
96,492,683 
Dilutive effect on number of shares 
- 
- 
Weighted average number of common shares outstanding for diluted earning per share calculation 
153,471,109 
96,492,683 
 
For the year ended December 31, 2021, warrants, compensation options, compensation warrants, outstanding 
stock options and outstanding DSUs and RSUs to acquire 8,788,115 shares (2020 – 4,507,349) have been 
excluded from the above calculation since their inclusion would have had an anti-dilutive effect. 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(32) 
 
8 
Trade and other receivables 
 
 
2021 
$ 
2020 
$ 
Current trade receivables 
21,153 
5,702 
Past due trade receivables 
 
 
1-30 days 
6,921 
2,932 
31-60 days 
2,145 
3,242 
61-90 days 
2,987 
2,675 
Greater than 90 days 
5,271 
4,004 
Total trade receivables 
38,477 
18,555 
Contract assets (Note 16) 
10,623 
7,767 
Related party receivables (Note 27) 
1,141 
- 
Other receivables 
656 
724 
Taxes receivable 
5,105 
2,696 
Supplier deposits 
7,104 
6,792 
Less: Allowance for expected credit loss  
(1,536) 
(1,411) 
Trade and other receivables - net 
61,570 
35,123 
 
Changes in allowance for expected credit loss are as follows: 
 
 
2021 
$ 
2020 
$ 
Allowance for expected credit loss, beginning of year 
(1,411) 
(534) 
Additions 
Additions – Business acquisition UEC 
(372) 
(263) 
(877) 
Unused amounts reversed 
369 
- 
Foreign currency exchange differences 
141 
- 
Allowance for expected credit loss, end of year 
(1,536) 
(1,411) 
 
9 
Inventories 
 
2021 
$ 
2020 
$ 
Raw materials 
41,123 
11,955 
Work in progress 
10,500 
8,229 
Sub-assembly parts 
1,070 
961 
Inventories 
52,693 
21,145 
 
Cost of goods sold includes inventories of $64,570 in 2021 ($35,334 in 2020).  
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(33) 
 
10 Finance lease receivables 
The Company has entered into finance leases on Gas-as-a-Service (GaaS) contracts through its subsidiary Green 
Vision B.V. consisting of gas generating systems. The lease terms are 15 years, which represents substantially all 
of the economic life of the systems.  
Future minimum rentals receivable under those non-cancellable finance leases, including the undiscounted lease 
payments to be received, are as follows: 
 
 
2021 
$ 
2020 
$ 
Less than one year 
725 
271 
Between 1-2 years 
725 
271 
Between 2-3 years 
725 
271 
Between 3-4 years 
725 
271 
Between 4-5 years 
725 
271 
More than five years 
6,318 
2,403 
      
9,943 
3,758 
Unguaranteed residual value (discounted) 
2,037 
731 
Unearned finance income  
(2,441) 
(1,303) 
Allowance for expected credit losses of finance lease receivables 
(76) 
(41) 
Total finance lease receivables 
9,463 
3,145 
Current portion of finance lease receivables 
410 
129 
Non-current portion of finance lease receivables  
9,053 
3,016 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(34) 
 
11 Property, plant and equipment 
 
 
 
 
 
 
 
 
 
Right-of-use-
assets 
Machinery and 
Production 
Equipment 
Office furniture 
and Equipment 
Leasehold 
Improvement 
Assets under 
construction 
Leased 
Equipment 
Total  
 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
Net book value 
 
 
 
 
 
 
 
As at December 31, 2019 
2,168 
491 
214 
154 
- 
- 
3,027 
Additions 
628 
234 
212 
54 
- 
- 
1,128 
Additions through 
business acquisition 
5,255 
7,025 
1,970 
98 
10,849 
8,429 
33,626 
Disposals 
- 
(6) 
(3) 
- 
- 
- 
(9) 
Depreciation 
(762) 
(170) 
(168) 
(33) 
- 
- 
(1,133) 
Effect of movements in 
exchange rates 
(51) 
2 
(9) 
(3) 
- 
- 
(61) 
As at December 31, 2020 
7,238 
7,576 
2,216 
270 
10,849 
8,429 
36,578 
Additions 
4,146 
2,515 
1,224 
550 
4,781 
212 
13,428 
Additions through 
business acquisition 
5,705 
1,998 
1,100 
411 
- 
- 
9,214 
Disposals 
(961) 
(46) 
(27) 
(4) 
(7,360) 
86 
(8,312) 
Depreciation 
(2,966) 
(1,039) 
(747) 
(144) 
- 
(920) 
(5,819) 
Transfers and others 
128 
(5,486) 
(40) 
- 
             3,872 
2,655 
1,129 
Effect of movements in 
exchange rates 
(405) 
(480) 
(134) 
(8) 
(1,836) 
(668) 
 (3,531) 
As at December 31, 2021 
12,885 
5,039 
3,591 
1,074 
10,305 
9,793 
42,687 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Right-of-use-
assets 
Machinery and 
Production 
Equipment 
Office furniture 
and Equipment 
Leasehold 
Improvement 
Assets under 
construction 
Leased 
Equipment 
Total  
 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
Cost 
8,426 
8,429 
2,847 
321 
10,849 
8,429 
39,301 
Accumulated depreciation 
(1,188) 
(853) 
(631) 
(51) 
- 
- 
(2,723) 
Net book value as at 
December 31, 2020 
7,238 
7,576 
2,216 
270 
10,849 
8,429 
36,578 
Cost 
17,040 
6,931 
4,969 
1,269 
10,305 
10,713 
51,227 
Accumulated depreciation 
(4,155) 
(1,892) 
(1,378) 
(195) 
- 
(920) 
(8,540) 
Net book value as at 
December 31, 2021 
12,885 
5,039 
3,591 
1,074 
10,305 
9,793 
42,687 
 
 
 
 
 
 
 
 
 
Lease equipment 
The Company has entered into operating leases on GaaS contracts through its subsidiary Green Vision B.V. 
consisting of gas generating systems. These leases have terms of between five and ten years. 
Future minimum rentals receivable under non-cancellable operating leases are as follows: 
 
 
2021 
$ 
2020 
$ 
Within one year  
332 
415 
Between 1-2 years 
332 
346 
Between 2-3 years 
232 
187 
Between 3-4 years 
27 
187 
Between 4-5 years 
- 
187 
More than five years 
- 
- 
Total undiscounted lease payments receivable 
923 
1,322 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(35) 
 
Depreciation of $5,819 (2020 – $1,133) is included in the consolidated statement of loss for the year ended 
December 31, 2021: $2,240 (2020 – $344) in cost of goods sold; $3,579 (2020 – $789) in selling and 
administrative expenses; and $NIL (2020 – $834) in R&D expenses. 
The amount of borrowing costs capitalized as at December 31, 2021 was $446 (2020 – $468). 
 
12 Intangible assets 
 
Software 
Customer 
Relationships 
 
Development
costs
Engineering 
standardisation
Technology
Trademarks
Total 
intangible 
assets 
 
$
$ 
$
$ 
$
$
$ 
Net book value 
 
 
 
 
 
 
 
As at December 31, 2019 
116
3,563 
-
1,811
-
199
5,689 
Additions 
690
- 
-
362
-
-
1,052 
Additions through business acquisitions 
72
29,311 
44
-
25,535
9,175
64,137 
Reclassification 
-
(16) 
-
(277)
-
-
(293) 
Amortization 
(74)
(605) 
-
(1,922)
-
(51)
(2,652) 
Effect of movements in exchange rates 
1
(327) 
-
26
-
(31)
(331) 
Balance at December 31, 2020 
805
31,926 
44
-
25,535
9,292
67,602 
Additions 
1,214
- 
-
-
-
1,214 
Additions through business acquisitions 
5
17,571 
-
-
5,931
8,878
32,385 
Reclassification 
-
- 
-
-
-
- 
Amortization 
(648)
(3,376) 
(44)
-
(1,465)
(815)
(6,348) 
Effect of movements in exchange rates 
393
(2,970) 
-
-
(1,184)
(2,272)
(6,033) 
Balance at December 31, 2021 
1,769
43,151 
-
-
28,817
15,083
88,820 
 
 
 
 
 
Software
Customer 
Relationships 
 
Development
costs
Engineering 
standardisation
Technology
Trademarks
Total 
intangible 
assets 
 
$
$ 
$
$
$
$
$ 
Cost 
1,216
32,576 
345
3,245
25,535
9,341
72,258 
Accumulated depreciation 
(411)
(650) 
(301)
(3,245)
-
(49)
(4,656) 
Balance at December 31, 2020 
805
31,926 
44
-
25,535
9,292
67,602 
Cost 
2,435
48,859 
-
-
29,105
17,561
97,960 
Accumulated depreciation 
(666)
(5,708) 
-
-
(288)
(2,478)
(9,140) 
Balance at December 31, 2021 
1,769
43,151 
-
-
28,817
15,083
88,820 
 
The amount of borrowing costs capitalized as at December 31, 2021 was $471 (2020 – $491). 
Amortization of $6,348 (2020 – $2,652) is included in the consolidated statement of loss for the year ended 
December 31, 2021: $44 (2019 – $1,088) in cost of goods sold; and $6,304 (2020 – $730) in selling and 
administrative expenses and $Nil (2020 – $834) in R&D expenses. 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(36) 
 
13 Goodwill 
The movements in the net carrying amount of goodwill are as follows: 
 
2021 
$ 
2020 
$ 
Carrying amount – Beginning of year  
117,842 
3,504 
Acquired through business combinations  
54,136 
114,611 
Net exchange difference 
(8,514) 
(273) 
Carrying amount – End of the year  
163,464 
117,842 
 
During the fourth quarter of 2021, the Company performed a test of impairment of its goodwill. For the purpose 
of annual impairment testing, goodwill is allocated to the following CGUs: 
 
2021 
$ 
2020 
$ 
Systems 
121,554 
109,184 
Support 
41,910 
8,658 
Total goodwill   
163,464 
117,842 
 
As at December 31, 2020, the impairment testing was performed at the subsidiary level.  Following the current 
year acquisitions, the Company reorganized it’s reporting structure. This reorganization did not change the 
CGU’s, but did change the level at which the Company monitors goodwill. Goodwill is now monitored at the 
operating segment level, with each operating segment representing a group of CGUs. Corporate assets of the 
Company have been allocated to a CGU group on a reasonable and consistent basis for purposes of impairment 
testing. 
From the 2020 presentation, HyGear and ACS are now presented in Systems.  CAI, CDA, Air Flow and Titus are 
presented in Support. 
From the 2021 acquisitions, Inmatec and UEC are now presented in Systems. Nortec, Tiger, California 
Compression and Wisconsin Compressed Air are presented in Support. 
The recoverable amount, which is the greater of its fair value less costs to sell (“FVLCTS”) or value in use 
(“VIU”), was compared to the carrying amount of the CGU to determine whether or not an impairment loss should 
be recorded against the goodwill.  
FVLCTS was determined using the prior transaction method (market approach). VIU was determined using the 
discounted future cash flow method (income approach), covering a detailed five-year forecast, using a discount 
rate from 10.5% to 12.9% (2020 – 15.7% to 24%) and a growth rate of 4% (2020 – 3%). The growth rate reflects 
the minimum long-term growth rate for the acquisitions. The discount rate reflects appropriate adjustments 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(37) 
 
relating to market risk and specific risk factors for the subsidiaries. Management’s key assumptions include stable 
gross profit margins over the forecast period based on past experience. 
The recoverable amounts were estimated to be higher than the carrying amounts and no impairments were 
required.  
14 Credit facility 
In February 2021, the Company secured credit facilities with National Bank of Canada’s Technology and 
Innovation Banking Group for a total value of up to $59,250 bearing interest of CDOR plus applicable margin. 
The credit facilities are secured by a first ranking hypothec of $75,000 on all movable property of the Company. 
In addition, a financial account was put in place by National Bank of Canada as a first ranking hypothec for Debt-
related Guarantees. As at December 31, 2021 the Company had $11,400 in this account. 
In March 2021, the Company renewed its Account Performance Security Guarantee (“Account PSG”) Facility 
with EDC for an amount not to exceed $10,000. The validity period of this facility is from January 1, 2021 to 
December 31, 2021.  
As at December 31, 2021, an amount of $5,000 was outstanding under the Operating and Acquisition Credit 
Facility (NIL as at December 31, 2020) and an amount of $6,876 was outstanding under the Letters of Guarantee 
Credit Facility ($3,953 as at December 31, 2020), of this amount, $5,763 is under the Account PSG facility. In 
addition, only the Credit Card Facility was used at the end of the year.  
As at December 31, 2021 Standby Fees of 0.60% are applicable on the unused portion of the Operating and 
Acquisition Credit Facility and the Pre-Shipment Credit Facility. 
The Xebec Adsorption Shanghai Co. bank loan is not consolidated in 2021 due to change in ownership (note 25) 
($975 as at December 31, 2020). 
During the year ended December 31, 2021, all applicable financial covenants and conditions were respected by 
the Company. 
15 Trade, other payables and accrued liabilities 
 
2021 
$ 
2020 
$ 
Trade payables 
24,016 
20,060 
Accrued liabilities 
8,349 
7,034 
Taxes payable 
818 
197 
Payables to related parties (Note 26) 
65 
3 
Other payables 
111 
277 
Other payables and accrued liabilities 
33,359 
27,571 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(38) 
 
16 Contract balances 
Contract assets: 
 
2021 
$ 
2020 
$ 
Cost incurred and recorded margins 
57,407 
32,576 
Addition through business acquisition  
- 
2,238 
Less: advances and progress billing 
(46,784) 
(27,047) 
 
10,623 
7,767 
 
Contract assets are included in trade and other receivables in the consolidated statements of financial position 
(Note 8).  
Contract liabilities: 
 
2021 
$ 
2020 
$ 
Advances and progress billings 
67,023 
14,144 
Addition through business acquisition  
- 
2,940 
Less: cost incurred and recorded margin 
(37,293) 
(9,577) 
 
29,730 
7,507 
 
Commercial and R&D contracts include government grants of $1,952 (2020 – $1,915).  
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(39) 
 
17 Long-term debt and government royalty program obligation 
Long-term debt 
 
Notional 
Repayment 
 
2021 
 
2020 
 
Amount 
Period 
Current 
Non-Current 
Current 
Non-Current 
NAPEX Bonds 
 
 
 
 
 
 
        Euro, fixed rate – 7.0% to 8.0% 
12,497 
2025 
- 
17,636 
- 
18,889 
EDC Loan 
 
 
 
 
 
 
        U.S. dollar, 7.5% 
14,833 
2022-2028 
2,728 
16,141 
- 
- 
Subordinated loans 
 
 
 
 
 
 
        Euro, fixed rate – 7% to 8.0% 
683 
2023-2024 
- 
983 
234 
8,937 
Unsecured loan facility1 
 
 
 
 
 
 
        Canadian dollar, fixed rate –8.5% 
and 9.0% 
15,000 
2025 
- 
10,119 
- 
3,589 
Lease liabilities 
 
 
 
 
 
 
        Euro, variable rate  
 
 
1,150 
2,682 
721 
2,871 
        U.S. dollar, variable rate 
 
 
1,581 
4,652 
345 
1,458 
        Canadian dollar, variable rate 
 
 
848 
2,900 
388 
2,017 
        Other, variable rate 
 
 
94 
219 
138 
- 
Innovation loan HYREC 
 
 
 
 
 
 
        Euro, fixed rate – 7.0% 
 
 
- 
- 
3,005 
- 
Bank loans 
 
 
 
 
 
 
        Euro, fixed rate – 2.4% to 4.65% 
1,644 
2022-2024 
1,063 
1,355 
341 
634 
Contingent consideration 
 
 
 
 
 
 
        Canadian dollar 
 
 
215 
- 
- 
- 
        U.S. dollar 
 
 
- 
2,734 
201 
2,133 
        GBP 
 
 
630 
1,633 
- 
- 
Business acquisition balance payable 
 
 
 
 
 
 
        Euro 
 
 
4,265 
- 
6,556 
- 
        U.S. dollar 
 
 
794 
7,662 
756 
1,083 
        Canadian dollar 
 
 
180 
- 
778 
- 
Government assistance (Covid-19) 
 
 
 
 
 
 
        U.S. dollar 
 
 
- 
- 
579 
422 
Other loans 
 
 
 
 
 
 
        Canadian dollar 
 
 
12 
2 
- 
- 
        U.S. dollar 
 
 
88 
83 
- 
- 
        Euro 
 
 
87 
555 
- 
728 
 
 
 
13,735 
69,356 
14,052 
42,774 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(40) 
 
 
1On November 9, 2021, the Company and FSTQ entered into an amended and restated Loan Agreement, 
increasing the credit facility provided by FSTQ by $15.0 million to a total of $25.0 million and providing for the 
issuance of 4,500,000 warrants to FSTQ at an exercise price of $4.44 per warrant for a three-year term. 
Government royalty program obligation 
In 2012, the Company signed a settlement agreement with Technology Partnership Canada (“TPC”) with regard 
to the Company’s Fast Cycle Pressure Swing Adsorption and Gas Management systems and Pulsar Pressure 
Swing Adsorption project.  
The Company had to pay $250 at the execution of the agreement and $1,000 spread over four equal annual non-
interest-bearing payments, starting on January 31, 2013. Furthermore, the Company was liable to pay up to $750 
in contingent payments based on proceeds from the sale by the Company of its intellectual property. In February 
2017, a new amendment to this agreement was reached extending the payment terms to January 1, 2023.  
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(41) 
 
Reconciliation of liabilities arising from financing activities 
 
 
 
 
 
 
 
Long-term 
debt 
Government 
royalty 
obligation 
program 
Obligation 
arising from 
non-
controlling 
interest 
participation 
in a 
subsidiary 
Leases 
liabilities 
Total 
Balance as at December 31, 2019 
3,727 
466 
4,180 
2,396 
10,769 
Cash flows:  
 
 
 
 
 
Financing fees 
(20) 
- 
- 
- 
(20) 
Balance of acquisition paid 
(102) 
- 
- 
- 
(102) 
Payments 
(6,604) 
(118) 
(1,731) 
(954) 
(9,407) 
Proceeds 
10,061 
- 
- 
- 
10,061 
Non-cash:  
 
 
 
 
 
Accretion 
263 
20 
306 
308 
897 
Sale price adjustment 
(221) 
- 
- 
- 
(221) 
Equity component 
(2,954) 
- 
- 
628 
(2,326) 
Additions through business combination 
43,749 
- 
- 
5,612 
49,361 
Deferred financing fees 
1,477 
- 
- 
- 
1,477 
Net exchange variation 
(488) 
- 
217 
(52) 
(323) 
Balance as at December 31, 2020 
48,888 
368 
2,972 
7,938 
60,166 
Cash flows:  
 
 
 
 
 
Balance of acquisition paid 
(3,526) 
- 
- 
- 
(3,526) 
New financing 
28,834 
- 
- 
- 
28,834 
Payments 
(12,434) 
(175) 
- 
(1,927) 
(14,536) 
Non-cash:  
 
 
 
 
 
Accretion 
1,074 
14 
120 
537 
1,745 
Addition 
67 
- 
- 
3,531 
3,598 
Debt forgiveness 
(1,000) 
- 
- 
- 
(1,000) 
Additions through business combination 
13,506 
- 
- 
5,705 
19,211 
Disposal 
- 
- 
- 
(70) 
(70) 
Effect of deconsolidation 
- 
- 
(3,047) 
- 
(3,047) 
Deferred financing fees 
(3,616) 
- 
- 
- 
(3,616) 
Adjustment 
(195) 
- 
- 
(961) 
(1,156) 
Net exchange variation 
(2,634) 
- 
(45) 
(626) 
(3,305) 
Balance as at December 31, 2021 
68,964 
207 
- 
14,127 
83,298 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(42) 
 
18 Provisions 
Warranty provisions 
 
 
2021 
$ 
2020 
$ 
Balance – Beginning of year 
1,889 
174 
Additions through business combination 
2,731 
 
Provision for the year 
209 
1,715 
Balance – End of year, 
4,829 
1,889 
Current portion of provision 
(1,780) 
(1,541) 
Non-current provision 
3,049 
348 
The Company offers warranties for 18 months after shipping or 12 months after start-up to the purchasers of its 
gas purification and natural gas dryers.  
As at December 31, 2021, the provisions include an amount of $1,550 (2020 – $1,297) for anticipated losses on 
long-term production type contracts.   
19 Obligation arising from shares issued by subsidiary 
In September 2015, as a result of a Sino-foreign equity joint venture agreement, Xebec Adsorption (Shanghai) 
Co. Ltd., issued 1,714,285 common shares, representing a 30% participation, to Shanghai Chengyi New Energy 
Venture Capital Co. Ltd. (28.26%), an investment subsidiary of Shanghai based Shenergy Group, Shanghai Zhiyi 
Enterprise Management Consulting Co. Ltd. (0.1%) and Shanghai Liuhuan Investment Co. Ltd. (1.64%), a 
company held by a group of employees of Xebec Adsorption (Shanghai) Co. Ltd., (collectively the “Minority 
Shareholders”) for a net cash consideration of $3,423 (RMB 16,371).  
Pursuant to this agreement, the Company had the obligation to repurchase the Minority Shareholders’ interest in 
Xebec Adsorption (Shanghai) Co. Ltd., for a consideration of no less than the initial investment and annualized 
return of 10% if a) the achievement of specific financial targets were not achieved in any given year prior to 
December 31, 2020, or b) should the Minority Shareholders not divest by December 31, 2020 and should the 
Minority Shareholders exercise their put option with respect to a) or b) as mentioned above.  
On July 24, 2018, the Minority Shareholders of Xebec Adsorption (Shanghai) Co. Ltd. and the Company agreed 
that the Company would pay the Minority Shareholders $187 (RMB 1,000) per year including 2018 until the EDC 
loan expiry or latest up to December 31, 2020 (whichever is earlier). The annual fees was to be considered a 
deduction to the repurchase price at the time of repurchase. As the negotiations was ongoing with the Minority 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(43) 
 
Shareholders, the Company did not fulfill its repurchase obligation according to the original agreement by paying 
the full repurchase price in one lump sum.  
In 2019 and 2020 no payments of the annual fee were processed. A conditional amount of $1,731 was paid in 
December 2020 based of the achievement of some performance targets as agreed by both parties. 
On July 25, 2018, the Minority Shareholders of Xebec Adsorption (Shanghai) Co. Ltd, agreed that, for a period 
beginning on the date hereof up to the date that Export Development Canada has been repaid in full (including 
capital, interests and fees) under the EDC Financing Arrangement, it shall not exercise any of its divestment, 
refund, compensation and other equity repurchase rights. 
The Company recorded the proceeds from this transaction, as a financial liability in these consolidated financial 
statements. The obligation to repurchase and the related annualized return is presented under “Obligation arising 
from shares issued by a subsidiary”. The conversion of the financial liability denominated in the functional 
currency of our subsidiary Xebec Adsorption (Shanghai) Co. Ltd. (RMB) was to be converted at the exchange 
rate at the end of each reporting period with gain and losses presented in the statement of income (loss) under 
“Gain/Loss on conversion of shares issued by a subsidiary”. 
 
2021 
$ 
2020 
$ 
Balance – Beginning of year 
2,972 
4,180 
Accretion interest 
120 
306 
Conditional reimbursement 
- 
(1,731) 
Effect of deconsolidation 
(3,047) 
- 
Net exchange variation 
(45) 
217 
Balance – End of Year 
- 
2,972 
Current portion 
- 
2,792 
 
 
20 Long term incentive plan 
The Company has a long-term incentive plan (LTIP) that permits the granting of options (“LTIP Options”), 
Restricted Stock Units (“RSUs”) and Deferred Share Units (“DSUs”), (collectively the “Awards”) to eligible 
participants of the Company and is administered with the oversight of the Human Resources Committee.  
The total number of common shares reserved and available for grant and issuance pursuant to Awards (including 
the common shares issuable upon exercise of the outstanding options previously granted under the Legacy Stock 
Option Plan) shall not exceed a number of common shares equal to 17,791,757. 
The aggregate number of common shares issuable to all participants retained, within any one-year period, under 
the LTIP, or when combined with all of the Corporation’s other security-based compensation arrangements, shall 
not exceed 2% of the Corporation’s total issued and outstanding securities, calculated on the date the Award is 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(44) 
 
granted to the participant, and options granted to such participants must vest in stages over a period of not less 
than one year with no more than ¼ of the options vesting in any three month period. 
The exercise price under an option is determined by the Human Resources Committee and shall not be less than 
100% of the fair market value of a common share on the date of grant of such option. The term of each option 
shall be fixed by the Committee at the date of grant but shall not be longer than 10 years from the date of grant. 
Share-based payments expense capitalized in contributed surplus are as follows: 
 
 
2021 
$ 
2020 
$ 
LTIP options 
(52) 
180 
DSU 
294 
203 
RSU 
746 
669 
Total share-based payments expense capitalized in contributed surplus 
988 
1,052 
 
Legacy Stock Options Plan  
Changes in legacy stock options are as follows: 
 
 
2021 
 
2020 
 
Number 
of options 
 
Weighted 
average 
exercise 
price 
$ 
Number 
of options 
Weighted 
average 
exercise 
price 
$ 
Outstanding – Beginning of year 
2,178,528 
0.48 
4,081,860 
0.35 
Exercised                     
(83,334) 
0.57 
(1,903,332) 
0.19 
Forfeited  
(1,308,194) 
0.53 
- 
- 
Expired 
- 
- 
- 
- 
Outstanding – End of year 
787,000 
0.40 
2,178,528 
0.48 
Exercisable – End of year 
687,000 
0.38 
1,700,194 
0.45 
 
The average share price for the exercised options was $3.70 (2020 – $4.27). 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(45) 
 
As at December 31, 2021, options outstanding and exercisable are as follows: 
 
 
 
 
 
Expiry date 
Weighted-
Average 
Exercise 
Price 
$ 
Number of 
Options 
Outstanding 
Weighted-
Average 
Remaining 
life 
Number of 
Options 
exercisable 
December 19, 2022    
 0.55 
200,000 
0.97 
200,000 
January 7, 2023 
0.05 
200,000 
1.02 
200,000 
August 29, 2024 
0.49 
350,000 
2.66 
250,000 
December 19, 2024 
0.55 
37,000 
2.96 
37,000 
 
0.40 
787,000 
1.83 
687,000 
 
Stock options (LTIP options)  
Changes in LTIP options are as follows: 
 
 
2021 
 
2020 
 
Number 
of options 
 
Weighted 
average 
exercise 
price 
$ 
Number 
of options 
Weighted 
average 
exercise 
price 
$ 
Outstanding – Beginning of year 
- 
- 
- 
- 
Granted                     
50,000 
5.01 
- 
- 
Outstanding – End of year 
50,000 
5.01 
- 
- 
Exercisable – End of year 
- 
- 
- 
- 
 
The fair value of the options was $166, which was estimated using the Black Scholes Option Pricing Model with 
the following assumptions: 
Risk-free interest rate 
 
1.42% 
Annualized volatility 1  
 
70.10% 
Share price 
 
$5.01 
Expected life of compensation options 
 
7 years 
 
1 The expected volatility used was based in the historic volatility of the Company’s share price 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(46) 
 
As at December 31, 2021, options outstanding and exercisable are as follows: 
Expiry date 
Weighted-
Average 
Exercise 
Price 
Number of 
Options 
Outstanding 
Weighted-
Average 
Remaining 
life 
Number of 
Options 
exercisable 
May 21, 2028    
 $5.01 
50,000 
6.4 
- 
 
$5.01 
50,000 
6.4 
- 
 
DSU  
Changes in DSU are as follows: 
 
 
 
 
2021 
2020 
 
Number 
of DSU 
Number 
of DSU 
Outstanding – Beginning of year 
66,231 
- 
Granted  
70,266 
66,231 
Exercised  
(8,883) 
- 
Outstanding – End of year 
127,614 
66,231 
 
In the year ended December 31, 2021, DSUs were granted under the Corporation’s Stock Incentive Compensation 
Plan to directors of the board and a consultant of the Company for a fair value of $236 (2020 – $261). The DSU 
granted in 2021 vested on grant date. The DSU granted in 2020 vest in stages until June 2021. 
RSU  
Changes in RSU are as follows: 
 
2021 
2020 
 
Number 
of RSU 
Number 
of RSU 
Outstanding – Beginning of year 
265,300 
- 
Granted  
180,501 
265,300 
Cancelled 
(52,858) 
- 
Exercised  
(19,442) 
- 
Outstanding – End of year 
373,501 
265,300 
 
In the year ended December 31, 2021, RSUs granted under the Corporation’s Stock Incentive Compensation Plan 
to employees of the Company had a fair value of $934 (2020 – $2,103). The RSU will vest in stages until May 
2024 (2020 – November 2023). 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(47) 
 
21 Supplemental Cash flow information  
Changes in non-cash working capital balances are as follows: 
 
 
2021 
$ 
2020 
$ 
Cash (used in) provided by non-cash working capital: 
 
 
          Trade and other receivables 
(16,430) 
3,233 
          Inventories 
(25,630) 
(9,302) 
          Other current assets 
(100) 
(333) 
          Other non-current assets 
23 
(53) 
          Trade payables accrued liabilities 
(4,641) 
4,368 
          Contract liabilities 
19,289 
252 
          Income tax payable 
(263) 
(500) 
          Provisions 
284 
1,716 
 
(27,468) 
(619) 
Income tax paid 
1,695 
2,031 
Interest paid 
6,491 
3,233 
 
22 Employee compensation 
 
2021 
$ 
2020 
$ 
Salaries and short-term employee benefits 
38,314 
19,036 
Share-based compensation 
988 
1,052 
 
39,302 
20,088 
 
Total compensation for key management, which includes the Company’s senior management, for the year ended 
December 31, 2021 was $1,452 (2020 – $1,617); Salaries were $1,214 (2020 – $1,464) and share-based 
compensation were $238 (2020 – $153).  
23 Contingencies and commitments 
Contingencies 
In the normal course of operations, the Company is party to a number of lawsuits, claims and contingencies.  
Although it is possible that liabilities may be incurred in instances for which no accruals have been made, the 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(48) 
 
Company does not believe that the ultimate outcome of these matters will have a material impact on its 
consolidated position. 
Commitments 
Contractual obligations and commitments that are not recognized as liabilities are as follows: 
 
2021 
$ 
2020 
$ 
Less than 1 year 
3,678 
391 
Between 1 and 5 years 
794 
228 
Total commitments 
4,472 
619 
 
Leases include various equipment leases.  Lease expense for year ended December 31, 2021 amounted to $3,377 
(2020 – $295). 
24 Capital management 
The Company’s objective when managing capital is to use short-term funding sources to manage its working 
capital requirements and fund capital expenditures required to execute its operating and strategic plans. 
Management monitors the solvency ratios at the end of the year as some debts include a solvency ratios.  
The Company’s capital structure is composed of the following: 
 
2021 
$ 
2020 
$ 
Cash 
(39,905) 
(160,938) 
Restricted cash 
(11,214) 
(7,642) 
Long-term debt (Note 17) 
83,091 
56,826 
Government royalty program obligation (Note 17) 
207 
368 
Obligation arising from shares issued by a subsidiary 
- 
2,972 
Net debt 
32,179 
(108,414) 
Equity 
314,810 
344,033 
 
346,989 
235,619 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(49) 
 
The Company is not subject to any capital requirements imposed by regulators. 
25 Financial instruments 
Measurement categories and fair values, including valuation methods and assumptions 
The carrying values of cash, restricted cash, trade and other receivables, trade and other payables, accrued 
liabilities and credit facility approximate their fair value due to their short-term maturities. The methods and 
assumptions used in estimating the fair values of other financial assets and financial liabilities are as follows: 
• 
Long-term debt (classified in level 2 of the fair value hierarchy): The Company’s long-term debt carry 
fixed interest rates. The fair value of the Company’s debt obligations has been calculated by discounting 
the future cash flows of the long-term debt at the interest rate of similar debt instruments. 
• 
Government royalty program obligation (classified in level 2 of the fair value hierarchy): Fair value of 
the government royalty program obligation has been calculated by discounting the future cash flows at 
the interest rate for a similar loan in the market. 
• 
Obligation arising from shares issued by a subsidiary (classified in level 2 of the fair value hierarchy): 
Fair value of the obligation arising from shares issued by a subsidiary has been calculated by computing 
an annualized return of 10% on the initial consideration  
• 
The Company’s financial instruments that are measured subsequent to initial recognition at fair value and 
financial instruments measured at amortized cost for which the fair value is disclosed are grouped into 
Levels 1 to 3 based on the degree to which the fair value is observable: 
 
Level 1 — Fair value measurements are those derived from quoted prices (unadjusted) in active markets 
for identical assets or liabilities. 
Level 2 — Fair value measurements are those derived from inputs other than quoted prices included 
within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. 
derived from prices). 
Level 3 — Fair value measurements are those derived from valuation techniques that include inputs for 
the asset or liability that are not based on observable market data (unobservable inputs). 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(50) 
 
The following table shows the carrying values and fair values of assets and liabilities by category as of: 
 
 
 
 
 
 
 
2021 
 
2020 
 
Carrying 
amount 
$ 
Fair  
Value 
$ 
Carrying 
amount 
$ 
Fair  
Value 
$ 
Cash  
39,905 
39,905 
160,938 
160,938 
Restricted cash 
12,940 
12,940 
7,642 
7,642 
Trade and other receivables 
40,274 
40,274 
17,868 
17,868 
Other current assets 
- 
- 
16 
16 
Finance lease receivables 
9,463 
9,463 
3,145 
3,145 
Credit facility 
(5,000) 
(5,000) 
(975) 
(975) 
Trade, other payables and accrued liabilities 
(28,404) 
(28,404) 
(24,576) 
(24,576) 
Long-term debt 
(68,964) 
(74,749) 
(48,888) 
(48,329) 
Government royalty program obligation 
(207) 
(207) 
(368) 
(368) 
Obligation arising from shares issued by a subsidiary 
- 
- 
(2,972) 
(2,972) 
 
 
Credit risk 
Credit risk is the risk of an unexpected loss if a customer or third party fails to meet its contractual obligations. 
The Company’s primary credit risk is its cash, restricted cash, finance leases receivables and outstanding trade 
and other receivables. The carrying amount of its outstanding trade and other receivables represents the 
Company’s estimate of its maximum credit exposure.  
The Company determines whether the credit risk of a financial asset has increased significantly since initial 
recognition considering reasonable and supportable information that is relevant and available without undue cost 
or effort. This includes both quantitative and qualitative information and analysis, based on the Company’s 
historical experience and informed credit assessment and including forward-looking information.  
In addition, the Company is exposed to credit risk in relation to finance lease receivables and applies the simplified 
approach in IFRS 9 to measure the loss allowance at lifetime expected credit losses. 
 
The Company considers a financial asset to be in default when the customer is unlikely to pay its credit obligations 
to the Company in full without recourse by the Company to actions such as realising security (if any is held). 
For trade receivables, contract assets and finance leases receivables, Green Vision Holding B.V. applies the 
simplified approach in IFRS 9 to measure the loss allowance at lifetime expected credit losses. Green Vision 
Holding B.V. determines the expected credit losses on trade receivables and contract assets by using a provision 
matrix, estimated based on historical credit loss experience and the profile of payments within the trade 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(51) 
 
receivables (based on the invoice date), adjusted as appropriate to reflect current conditions and estimates of 
future economic conditions. 
The Company regularly monitors its credit risk exposure and takes steps such as employing credit-approval 
procedures, establishing credit limits, using credit assessments and monitoring practices to mitigate the likelihood 
of these exposures resulting in an actual loss.  
Trade and other receivables are reviewed on a weekly basis. All potential risks are provisioned and the amount 
on the consolidated financial statements reflects this analysis. 
As at December 31, 2021, the Company’s three largest trade debtors accounted for 16% (10%, 3% and 3%) of 
the total trade receivables balance (2020 – 32% (17%, 9% and 6%)). 
Details of trade and other receivables were as follows: 
 
2021 
$ 
2020 
$ 
Total trade receivables 
38,477 
18,555 
Related party receivables (Note 27) 
1,141 
- 
Other receivables 
656 
724 
Less: Allowance for expected credit loss  
(1,536) 
(1,411) 
Total trade and other receivables 
38,738 
17,868 
 
The Company’s cash and restricted cash are maintained at financial institutions with high credit ratings; therefore, 
the Company considers the risk of non-performance on this instrument to be remote. To date, the Company has 
not incurred any losses related to its cash.  
Market risk 
Currency risk 
Certain financial assets and financial liabilities are exposed to foreign exchange fluctuations. Taking into account 
the amounts denominated in the currencies indicated below and assuming that all of the other variables remain 
unchanged, a fluctuation in exchanges rates would have an impact on the Company’s net income (loss). 
Management believes that a 10% change in exchange rates of all currencies indicated would be reasonably 
possible and that the impact on net income (loss) of such a change would be approximately $3,764 for 2021 (2020 
– $749). As at December 31, 2021, the following accounts are shown in their original currencies and converted 
into Canadian dollars. The Company does not use financial instruments to reduce this risk. 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(52) 
 
 
 
 
 
 
 
 
 
 
 
2021 
 
 
2020 
 
US 
dollar 
Euro 
British 
Pound 
US 
dollar 
Euro 
British 
Pound 
Cash 
7,453 
2,247 
- 
711 
12 
- 
Trade and other receivables 
22,921 
6,426 
371 
4,685 
40 
- 
Trade and other payables 
(7,493) 
(2,923) 
(163) 
(203) 
(26) 
(1) 
 
22,881 
5,750 
208 
5,193 
26 
(1) 
Equivalent in Canadian dollars 
31,909 
9,103 
391 
6,612 
41 
(2) 
 
Interest rate risk 
Interest rate risk is the risk that the fair value of future cash flows from financial instruments will fluctuate as 
market interest rates change.  
The Company is exposed to interest rate risk on its credit facility, for which the interest rates charged fluctuate 
based on the bank’s prime rate. If the interest rate on the credit facility had been 50 basis points higher (lower), 
related to the credit facility as at December 31, 2021, the impact on the net income and equity would have been 
negligible.  
Liquidity risk 
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. 
The following are the contractual maturities of financial liabilities and other liabilities as at December 31: 
 
 
 
 
 
 
 
 
 
 
 
2021 
 
Carrying 
amount 
$ 
Contractual 
cash flow 
$ 
0 to 12 
months 
$ 
13 to 24 
months 
$ 
Thereafter 
 
$ 
Credit facility  
5,000 
5,000 
5,000 
- 
- 
Trade and other payables and accrued liabilities 
28,404 
28,404 
28,404 
- 
- 
Government royalty program obligation   
207 
207 
207 
- 
- 
Loan Fonds solidarité FTQ  
10,119 
15,000 
- 
- 
15,000 
Contingent liability  
5,212 
5,564 
1,701 
2,058 
1,805 
Other long-term debts 
40,732 
41,029 
4,914 
3,813 
32,302 
Business price balance acquisition payable 
12,901 
13,156 
5,334 
5,257 
2,565 
 
102,575 
108,360 
45,560 
11,128 
51,672 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(53) 
 
 
 
 
 
 
 
2020 
 
Carrying 
amount 
$ 
Contractual 
cash flow 
$ 
0 to 12 
months 
$ 
13 to 24 
months 
$ 
Thereafter 
 
$ 
Credit facility  
975 
975 
975 
- 
- 
Trade and other payables and accrued liabilities 
24,576 
24,576 
24,576 
 
 
Government royalty program obligation   
368 
388 
175 
190 
23 
Loan Fonds Solidarité FTQ  
3,589 
6,987 
450 
450 
6,087 
Government assistance 
1,001 
1,001 
1,001 
- 
- 
Contingent liability  
2,333 
2,359 
581 
999 
779 
Other long-term debts 
32,792 
33,605 
3,537 
528 
29,540 
Business price balance acquisition payable 
9,173 
9,376 
8,230 
573 
573 
Obligation arising from shares issued by a subsidiary 
2,972 
2,972 
2,972 
- 
- 
 
77,779 
82,239 
42,497 
2,740 
37,002 
 
Contractual interest amounts on floating interest rates are established based on the spot rates as at the statement 
of financial position dates. 
The Company’s development is financed through a combination of borrowing under the existing 
credit facilities and the issuance of debt and equity. 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(54) 
 
26 Related party relationship 
Investment in subsidiaries consolidated in the Company’s financial statements: 
 
 
 
Country of 
incorporation 
% equity 
interest 
2021 
% equity 
interest 
2020 
Applied Compression Systems LTD 
Canada 
100 
100 
California Compression, LLC 
USA 
100 
- 
CDA Systems, LLC 
USA 
100 
100 
Compressed Air International Inc. 
Canada 
100 
100 
Enerphase Industrial Solutions Inc. (Air Flow) 
USA 
100 
100 
GNR Québec Capital Management Inc 
Canada 
100 
100 
Green Vision Holding B.V. 
Netherlands 
100 
100 
HyGear B.V. 
Netherlands 
100 
100 
HyGear Fuel Cell B.V. 
Netherlands 
100 
100 
HyGear Hydrogen Plant B.V. 
Netherlands 
100 
100 
HyGear Operations B.V. 
Netherlands 
100 
100 
HyGear Technology and Services B.V. 
Netherlands 
100 
100 
Inmatec Gas Technology FZ-LLC 
UAE 
100 
- 
Inmatec Gase Technologie GmbH & Co.KG 
Germany 
100 
- 
Nortekbelair Corporation 
USA 
100 
- 
The Titus Company 
USA 
100 
100 
Tiger Filtration Limited 
UK 
100 
- 
UEC, LLC 
USA 
100 
- 
XBC Flow Services - Wisconsin Inc 
USA 
100 
- 
Xebec Adsoprtion USA Inc. 
USA 
100 
100 
Xebec Adsorption Asia PTE LTD 
Singapore 
100 
100 
Xebec Adsorption Europe SRL 
Italy 
100 
100 
Xebec Complimentar GmbH 
Germany 
100 
- 
Xebec Deutchland GMBH 
Germany 
100 
- 
Xebec Europe B.V. 
Netherlands 
100 
100 
Xebec Holding UK Limited 
UK 
100 
- 
Xebec Holding USA Inc. 
USA 
100 
100 
Xebec RNG Holdings Inc 
Canada 
100 
100 
 
 
 

Xebec Adsorption Inc. 
Notes to Consolidated Financial Statements 
For the years ended December 31, 2021 and 2020 
(expressed in Canadian dollars) 
 
(55) 
 
Investment in associates and joint ventures accounted for under the equity method: 
 
 
 
Country of 
incorporation 
% equity 
interest 
2021 
% equity 
interest 
2020 
Buse - HyGear LTD 
UK 
50 
50 
GNR Québec Capital S.E.C. 
Canada 
50 
50 
Xebec Adsorption (Shanghai) Co. LTD 1 
China 
60 
70 
 
1 On June 25, 2021, a new partnership with Shanghai based Shenergy Group Company Limited was approved by 
the Chinese authority. Xebec Shanghai received a direct equity investment of $3,400K in exchange for the debt 
and interest owed by Xebec for its share buyback obligation. Xebec Adsorption Inc. participation reduced from 
70% to 60%, along with changes to the shareholder agreement, which resulted in a change of control thus Xebec 
Shanghai have been deconsolidated from the date that control ceases. Following this transaction, the investment 
in the new partnership is recognised and presented as an equity investment. 
27 Related party transactions 
The following table presents a summary of the related party transactions during the period: 
 
2021 
$ 
2020 
$ 
Marketing and professional services expenses paid to companies controlled by members of the 
immediate family of an officer 
84 
80 
Rent paid to companies controlled by members of the immediate family of an officer 
240 
24 
Salaries and short-term benefits paid to members of immediate family of an officer 
186 
165 
Material purchased to companies controlled by members of the immediate family of an officer 
55 
34 
Total related party transactions 
565 
303 
 
The Company’s transactions and outstanding balances with equity accounted investees are as follows: 
 
2021 
$ 
2020 
$ 
Revenue 
700 
- 
Accounts receivables 
1,141 
-